• Author Index
• Abstract Index
• Subject Index
• Search
• Journal Homepage
• ISTH Homepage
• Online Journal
• Privacy Policy
• 2003
• 2005
• 2007
• 2009

Author Index

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

 

B
Büller H. R.	-	Tissue factor (TF) and high-sensitivity CRP (HS-CRP) in patients with peripheral arterial disease (PAD) undergoing peripheral bypass surgery or angioplasty: a retrospective study
Baarslag H.	-	Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremities: survival, risk factors and post–thrombotis syndrome
Babessa R. F.	-	Low molecular heparin in prophylaxis of thrombohamorragic complications after caesarean delivery in patients with cardiologic deseases
Babinska A.	-	Genomic structure, organization and promoter analysis of the human F11 receptor (F11R) (junctional adhesion molecule-1, JAM-1)
	-	The platelet adhesion receptor, F11R (a.k.a. JAM-1), is critical for the initiation of plaque formation, thrombosis and atherosclerosis
Babinska A.	-	Phosphorylation and expression of the extracellular domain of the platelet adhesion receptor, F11R (a.k.a. junctional adhesion molecule, JAM-1)
Babyn P.	-	Final results from the Canadian hemophilia dose escalation prophylaxis trial
Bacci C.	-	Dental implants in anti-coagulated out-patients
Bach R.	-	Tissue factor de-encryption
Bach R. R.	-	Intrasvascular tissue factor procoagulant activity increases following joint replacement surgery
Bachelot-Loza C.	-	ADP-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects
	-	Activation of pp125FAK by type 2B recombinant von Willebrand factor binding to platelet GPIb at high shear rate occurs independently of aIIb3 engagement
Bacher P.	-	Reviparin normalizes tissue factor pathway activation in patients with lower limb immobilization and is not associated with heparin antibody production
	-	Oral antithrombin agents comprise the regulatory functions of thrombin
	-	Alterations in intraplatelet Ca2+ mobilization by functional antiheparin-PF4 antibodies: Implications in the signaling mechanisms during HIT pathogenesis
	-	Considerations in the standardization of the functional and immunologic assays for human procarboxypeptidase U. Diagnostic implications
	-	Polypharmacologic actions of low-molecular-weight heparins: lessons from clinical trials
	-	Lower limb trauma is associated with a moderate risk of thrombosis caused by sustained release of tissue factor despite early functional mobilization
	-	Unfractionated heparin, but not a low-molecular-weight heparin (Clivarin), mediates differential generation of anti-heparin-PF4 antibodies in orthopedic surgery patients: Pathophysiologic and pharmacologic implications
	-	Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis
Bacheschi L. A.	-	Inherited prothrombotic risk factors in a Brazilian cohort with CVT
	-	Acquired prothrombotic-associated factors in cerebral venous thrombosis (CVT)
Bachli E. B.	-	Coagulation proteases factor Xa and factor VIIa do not mobilize intracellular calcium stores in human dermal fibroblasts
	-	Treatment of recurrent arterial thrombosis with hirudin in congenital afibrinogenaemia
Bachmeyer C.	-	Acquired protein S deficiency in HIV-infected patients is corrected under HAART
Bachoo P.	-	Enhanced in vivo platelet activation in patients with peripheral arterial disease, and differences between intermittent claudication and critical limb ischemia
	-	The CAVA study: a double-blind randomized controlled trial of clopidogrel and aspirin vs. aspirin alone in patients with intermittent claudication undergoing peripheral percutaneous transluminal angioplasty
Badellino K.	-	Binding to a negatively charged surface alters the conformation of factor XIa
Bader R.	-	A 3' untranslated region (3' UTR) variation on the factor VII (FVII) gene changes completely the phenotype due to the Arg277Cys mutation in a patient with Type I FVII deficiency
Bader-Meunier B.	-	Clinical and laboratory findings in a new case of congenital amegakaryocytic thrombocytopenia (CAMT)
Badescu L.	-	Platelet adhesion index and soluble E-selectin in the prediction of cardiovascular risk
Badescu M.	-	Platelet adhesion index and soluble E-selectin in the prediction of cardiovascular risk
Badescu M.	-	Platelet-mediated vasodilatation factor activated by Zinc on diabetic rats
Badescu L.	-	Platelet-mediated vasodilatation factor activated by Zinc on diabetic rats
Badid C.	-	Ischemia induces early and enhanced expression of a new transcription factor (6A3-5) in human and rat kidney vascular smooth muscle cells
Badimon L.	-	Local blockade of the collagen binding domain to vWF-A3 with Saratin decreases thrombotic risk in human atherosclerotic lesions
	-	Local blockade of vWF binding epitopes on damaged vessel wall exposed collagen with Saratin inhibits thrombotic risk at different hemodynamic conditions
Bagan-Triquenot A.	-	Protein C promoter polymorphisms are potential additional risk factors for cerebral venous thrombosis
Bagatella P.	-	Subcutaneous adjusted-dose unfractionated heparin vs. fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism
Bagga S.	-	Anti-platelet agents clopidogrel and aspirin inhibit expression of tissue factor procoagulant activity in patients with peripheral artery disease
Baggio M. S.	-	Thrombotic risk in first-degree relatives of factor V Leiden (FVL) and factor II G20210A carriers
	-	Procoagulant effects of raloxifene in postmenopausal women
Baggio G.	-	The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study
Baggs R. B.	-	Ultrasound improves myocardial perfusion in a canine model of myocardial infarction
Baghaipoor M.	-	Inhibitor against factor VIII in developing countries; the first case of immune tolerance induction in Iran
Baghaipoor M. R.	-	Identification of intron 1 and 22 inversion mutation in the factor VIII gene of 94 Iranian families with hemophilia A
	-	Effect of ergometric exercise on factor VIII coagulant activity in patients with mild and moderate hemophilia A
Baglia F. A.	-	Identification of a binding site for glycoprotein Iba in the Apple 3 domain of factor XI
	-	Factor XI-activation by thrombin on activated platelets requires both anion binding exosites I and II
Baglin T.	-	Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors
Baglin C.	-	Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors
Baglin T.	-	The use of corn trypsin inhibitor to reduce the effect of sample contact activation in assays utilizing low tissue factor
Bagoly S.	-	SRC-dependent signaling is a key step in the process of autoregulation of Mac-1 adhesive function in human PMN
Bahgat M.	-	Isolated thrombocytopenia as a preliminary feature of antiphospholipid syndrome in patients with chronic liver disease
Bahou W.F.	-	Human blood platelets: RNA transcript profiling using microarray and serial analysis of gene expression
Bahr W.	-	Duplex screening for quality assurance of postoperative thromboembolism prophylaxis in neurosurgery – Krefeld Study ‘Thrombo 2000’
Bai X.	-	Soluble platelet GPV: a new marker of thrombosis status
Bai X.	-	Establishment of urokinase receptor gene antisense RNA transfer system and its influence on uPAR expression in leukemia cells
Bai X.	-	The frequency of P475S polymorphism in von Willebrand factor-cleaving protease among Chinese population and its relevance to arterial thrombotic disorders
	-	A recombinant von Willebrand factor fragment inhibits binding of von Willebrand factor to glycoprotein Ib-IX
	-	Quantitative analysis of gene expression for vascular endothelial growth factor and its application
Baidya S.	-	Administration of gentamicin does not increase factor levels in severe hemophilia-B due to premature termination codons
Baikeev R.	-	Calcium ion-independent structure of the factor IX w-loop peptide, FIX(G4–Q11) and its interaction with phosphatidylserine
Baimuradova S. M.	-	Prophylaxis of main obstetric complications in pregnant women with anti-phospholipid syndrome and genetic forms of thrombophilia
Baird T. R.	-	Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells
Bajaj S. P.	-	The structural role of glycine-193 in serine proteases: active site investigations of Gly193Val mutant of factor IXa and crystal structure of factor VIIa/soluble tissue factor with a reversible inhibitor
Bajaj S. P.	-	Crystal structure of benzamidine-Factor VIIa/soluble tissue factor at 1.87 Å resolution: mapping of calcium, magnesium, sodium, and zinc sites in the Factor VIIa structure
Bajaj M. S.	-	Crystal structure of benzamidine-Factor VIIa/soluble tissue factor at 1.87 Å resolution: mapping of calcium, magnesium, sodium, and zinc sites in the Factor VIIa structure
	-	Congenital factor VII deficiency and thrombosis. Description of a novel mutation
Bajaj S. P.	-	Congenital factor VII deficiency and thrombosis. Description of a novel mutation
	-	Characterization of a monoclonal antibody to factor VIII: epitope mapping and mechanism of inhibition
Bajaj M. S.	-	Tissue factor and tissue factor pathway inhibitor expression by adherent monocytes and alveolar macrophages
Bajaj S. P.	-	Tissue factor and tissue factor pathway inhibitor expression by adherent monocytes and alveolar macrophages
Bajan K.	-	Elevated factor VIII: a possible link between periodontal disease and acute coronary syndrome
Bajetta M. T.	-	A 3' untranslated region (3' UTR) variation on the factor VII (FVII) gene changes completely the phenotype due to the Arg277Cys mutation in a patient with Type I FVII deficiency
Bajzar L.	-	Fibrinolysis within the procoagulant VX-2 tumor of rabbit lungs in vivo: Anti-angiogenic behavior of fibrin(ogen) degradation products
	-	The carboxypeptidase mediated down-regulation of fibrinolysis exhibits a threshold effect which is masked by the intrinsic instability of TAFIa
Bak H.	-	L305V/S314E/K337A/F374Y-Factor VIIa has dramatically enhanced intrinsic activity
Baker B.	-	Warfarin loading with a 5-mg daily dose for the first 3 days of treatment is safe and effective for the management of patients with venous thrombosis
Baker D.	-	rAHF-PFM development and quality assurance
Baker P.	-	Nitric oxide levels are up-regulated in patients with malignancy associated hypercoagulable state
Baker R.	-	Prophylaxis for long distance travel
Baker K. R.	-	Sensitivity and specificity of the abnormal optical waveform profile in the prothrombin time from patients with antiphospholipid antibodies
Baker R. I.	-	Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with nonmetastatic malignancy and venous thromboembolism (VTE)
	-	Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE)
	-	Prediction and prevention of thrombosis during pregnancy and oestrogen use
Baker P.	-	The development of an automated, real time, oral anticoagulant dosing module to enhance traditional computerized decision support software (CDSS)
Baker R. I.	-	Anti-phospholipid antibodies in ischemic stroke
Bakhos M.	-	Intimatan ameliorates the activation of human platelets by heparin/heparin antibody from patients with heparin-induced thrombocytopenia
	-	Pharmacodynamic profile of Intimatan as an antithrombotic agent for venous thrombosis
	-	A postoperative platelet count threshold contributes to an earlier diagnosis of heparin-induced thrombocytopenia and improved platelet recovery in cardiac surgery patients. The HITME (Heparin-Induced Thrombocytopenia Multicenter Evaluation) study
Bakhtiari K.	-	Prospective assessment of the diagnostic accuracy of the ISTH criteria for the diagnosis of DIC
Bakhtiari K.	-	Comparison of 2 d-dimer assays (MDA®d-dimer and Tina-quant®d-dimer) in patients with suspected recurrent deep venous thrombosis – an interim analysis
	-	High levels of coagulation factors IX or XI: risk factors for pulmonary embolism?
Bakowska A.	-	Thrombophilic risk factors of ischemic stroke in children
Bal dit Sollier C.	-	Influence of R353Q factor VII gene polymorphism on the plasma FVII levels in a French native population (The Fitenat Study)
	-	Differential geographic distribution of Factor V Leiden and Factor II Leiden in a French native population (the Fitenat study)
Bal Dit Sollier C.	-	Lack of correlation between HPA1 polymorphism and ADP induced platelet activation: study of a large cohort of normal subjects
Bal dit Sollier C.	-	There is no north/south gradient distribution of the plasma fibrinogen level and of the C-148T Fg genotype in a French native population (The Fitenat Study)
Bal dit Sollier C.	-	Prevention of wine consumption on thrombosis but not on atherosclerosis in ApoE-/- mice
Balabushevich N. G.	-	Development of novel delivery systems of aprotinin
Balasa V. V.	-	Legg-Perthe's disease and thrombophilia: a causal association?
Balasch J.	-	Effect of antiphospholipid antibodies in the activation of the contact complex: importance in the obstetric complications of the antipospholipid syndrome
Balbale S.	-	Effectiveness of polybrene neutralization of heparin and low-molecular weight heparin in plasma
Bald E.	-	Is plasma homocysteine concentration different in diabetic and nondiabetic stroke patient up to the age of 55?
Baldan N.	-	Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft
Baldessin F.	-	Risk factors for venous thromboembolism in chronically bedridden patients admitted to the Hospice Unit
Balducci D.	-	Role of polymorphonuclear (PMN) leukocyte activation in the formation of PMN-platelet aggregates in Essential Thrombocythemia (ET) and Polycythemia Vera (PV)
Balducci D.	-	The synthetic retinoic acid receptor (RAR)-gamma agonist CD437 reduces procoagulant activity and induces apoptosis in breast cancer cells
Balduini C.	-	Activation of p38 MAP kinase in human platelets stimulated by von Willebrand factor
Balestra D.	-	Correlation of the serum ferritin (SF) levels with cholesterol and body mass index (BMI) in patients with advanced atherosclerosis
Balezina O. P.	-	Thrombin accelerates regeneration of mouse peripheral nerve in vivo
Ball C.	-	Peptides from the C-terminal regions of ADAMTS-13 specifically block cleavage of ultra-large von Willebrand factor multimers on the endothelial surface under flow
Ballard J.	-	Severe factor VII deficiency caused by a new point mutation combined with a previously undetected gene deletion
Baller D.	-	The G allele of IL-6–174G/C polymorphism is a risk factor for restenosis after coronary stent implantation by increased inflammation and platelet activation
Ballmaier M.	-	Clinical and laboratory findings in a new case of congenital amegakaryocytic thrombocytopenia (CAMT)
Ballman K. V.	-	Genetic susceptibility of venous thromboembolism: role of the procoagulant, anticoagulant, fibrinolytic, and acute inflammation pathways
Balogh I.	-	Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding
	-	A novel mutation (1668delC) in the glycoprotein IIb (CD41) gene causing Glanzmann's thrombasthenia
Balta G.	-	Assessment of the role of various genetic risk factors in development of childhood cerebral thrombosis
Baltatzi M.	-	Acute ischemic strokes: LMWHs or aspirin administration and laboratory follow-up
	-	Acute ischemic strokes: LMWHs or aspirin administration and laboratory monitoring
Balthazor S. M.	-	Maternal immunization against ‘rare’ platelet antigens as a cause of neonatal alloimmune thrombocytopenic purpura (NATP)
Bamburg J. R.	-	Analysis of the Rho-kinase/LIM-kinase/cofilin signaling pathway in activated platelets
Bamford J.	-	Increased factor XIII B and decreased factor XIII A subunit antigen levels in insulin resistant South Asian patients with ischaemic stroke
	-	Increased coagulation factor XIII B subunit antigen and factor XIII biotin activity is associated with family history of stroke in South Asians
Banbula A.	-	In vitro assessment of inhibitory potential of plasma and whole blood toward exogenous plasmin
Bandinelli B.	-	Monitoring of heparin therapy during cardiopulmonary bypass by using three different devices that measure the activated clotting time
	-	Monitoring of heparin therapy during cardiopulmonary bypass by using three different devices that measure the activated clotting time
	-	Assessment of platelet function during cardiopulmonary bypass using two new "point of care" devices
Bandinelli B	-	Evaluation of the fibrinolytic capacity before and after venous occlusion performed by serum d-dimer test after standardized coagulation
Bandinelli R.	-	High plasma homocysteine concentrations in cerebrovascular patients with Fabry disease
Bandinelli B.	-	Optimization of human 14 000 oligonucleotide-microarrays and study design for the evaluation of gene expression profiling in cardiovascular diseases
Bando K.	-	Successful argatroban-anticoagulant management for left ventricular assist system implantation in two patients with heparin-induced thrombocytopenia type II
Banerjee P.	-	Genomic structure, organization and promoter analysis of the human F11 receptor (F11R) (junctional adhesion molecule-1, JAM-1)
Banfi C.	-	Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats
Bang K. W. A.	-	Senescent rabbit platelets, or rabbit platelets with experimentally shortened survival, are apoptotic with increased surface exposure of procoagulant phosphatidylserine (PS)
Bang K.W.A.	-	Procoagulant surface expression on activated human platelets persists despite increased aminophospholipid translocase activity
Bank I.	-	Risk assessment of venous thromboembolism in pregnant women with factor V Leiden, prothrombin 20210 A mutation, elevated factor VIII levels or mild hyperhomocystinaemia
	-	Patients' valuation of outcomes after venous thromboembolism
	-	The optimal duration of treatment with vitamin K antagonists in patients with a first episode of venous thromboembolism: a decision analytic approach
Bank I.	-	Increased risk for venous thromboembolism and myocardial infarction in family members of patients with prothrombin 20210 A mutation
Bank I.	-	The risk of pregnancy complications in women from families with thrombophilic defects
	-	Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Preliminary results of a family cohort study
	-	The balance between the benefits and risks of treatment with vitamin K antagonists as perceived by patients
Bank I.	-	Venous and arterial thromboembolic risk in first degree family members of patients with elevated plasma levels of clotting factor VIII:c
Bank I.	-	High levels of coagulation factors IX or XI: risk factors for pulmonary embolism?
	-	Absolute risk of venous thromboembolism (VTE) associated with a single or combined thrombophilic disorder. Preliminary results of a family cohort study
Banner D. W.	-	The active conformations of Factor VIIa and Factor IXa: biochemical, biophysical, chemical and crystallographic studies
Banno F.	-	Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease
Banovic M.	-	Reproducibility of anticoagulation therapy control tested on fresh and frozen plasma
Bansal V. K.	-	Prevalence of anti-Erythropoietin antibodies in end stage renal disease patients treated with recombinant Erythropoietin
Banyai S.	-	Tissue factor (TF) and high-sensitivity CRP (HS-CRP) in patients with peripheral arterial disease (PAD) undergoing peripheral bypass surgery or angioplasty: a retrospective study
Bao M.	-	CD84 signaling is a novel platelet stimulatory mechanism that occurs during platelet aggregation
Bao C.	-	Identification of two novel point mutations in XIII A chain gene associated with congenital deficiency in a Chinese FXIII deficiency family
Bar Y.	-	Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study
Baracchini C.	-	Association between fibrinogen levels and fibrinogen G-455 A polymorphism and preclinical atherosclerosis in the general population
Baranovskaya S. S.	-	Molecular risk factors are important causes for the thrombosis in childhood
Baranska P.	-	The role of vascular endothelial growth factor in an early phases of proangiogenic changes in human endothelial cells
	-	Down-regulation of PAI-1 expression by natriuretic peptides is mediated by MAPK cascade in human endothelial cells
Baranski A.	-	Use of LMWHs in patients with cancer
Barat N.	-	Analytical validation of the automated measurement on STA-R of the ristocetin cofactor activity (VWF:RCo) of von Willebrand factor
	-	Evaluation of automated measurement of ristocetin cofactor activity of von Willebrand factor on STA-R® in von willebrand disease: study in 154 patients
Barbarroja N.	-	A promising therapeutic strategy in acute promyelocytic leukemia (APL): disruption of MEK/ERK, arsenic and retinoids
	-	Increased tissue factor expression in monocytes from patients with anti-phospholipid syndrome depends on NFkB activation
Barbe M. F.	-	Regulation of connective tissue growth factor (CTGF) in synovial lining and modulation of the disease course of acute arthritis in an experimental model of rheumatoid arthritis by residues D793-P824 derived from thrombospondin-1-type 3 repeats
	-	Connective tissue growth factor (CTGF) expression in synovial lining is down regulated by residues D793-P824 derived from thrombospondin-1 type-3 repeats (TSP1) in an experimental animal model of rheumatoid arthritis
Barbieri S. S.	-	Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte transition into macrophages: critical role for NADPH oxidase
Barbui T.	-	The synthetic retinoic acid receptor (RAR)-gamma agonist CD437 reduces procoagulant activity and induces apoptosis in breast cancer cells
	-	IgG antiprothrombin antibodies from patients with antiphospholipid syndrome inhibit the inactivation of Factor Va by activated protein C
	-	Effect of the LMWHs dalteparin and enoxaparin on tissue factor and thrombomodulin expression by endothelial cells
	-	Role of polymorphonuclear (PMN) leukocyte activation in the formation of PMN-platelet aggregates in Essential Thrombocythemia (ET) and Polycythemia Vera (PV)
	-	A randomized clinical trial of oral anticoagulant therapy in patients with the antiphospholipid syndrome: the WAPS study
Barcellona D.	-	Visceral vein thrombosis: retrospective analysis of 53 cases in five Italian thrombosis
	-	G20210A prothrombin mutation and allele 4G of gene PAI-1 in deep vein thrombosis
	-	Fasting homocysteine levels in predicting post methionine loading test results
Barcellona D.	-	G20210A prothrombin mutation and factor V Leiden (G1691A) to address local health policy
Bardaux S.	-	Functional studies of P-selectin polymorphism's associated with coronary diseases
Barden A. E.	-	Prediction and prevention of thrombosis during pregnancy and oestrogen use
Bardin N.	-	Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration
Bareford D.	-	Platelet, coagulation and endothelial markers in primary thrombocythaemia
	-	Plasma P selectin must be measured in a citrated sample, not in serum
Barek L.	-	Functional studies of P-selectin polymorphism's associated with coronary diseases
Bargouth G.	-	Diagnosing pulmonary embolism with clinical assessment, d-dimer, venous ultrasound and helical computed tomography: a multicenter management study
Barillari G.	-	Efficacy of high purity, monoclonal factor IX concentrate for continuous infusion in an hemophilia B patient undergoing orthopedic surgery
	-	Safety, efficiency and dose saving of continuous infusion modality of protein C concentrate in the management of a protein deficient patient submitted to orthopedic surgical procedure
	-	Safety and efficacy of nadroparin for the treatment or prophylaxis of venous thromboembolism in pregnancy
Barillari G.	-	In vivo recovery, efficacy and safety of solvent/detergent treated plasma in patients with rare inherited bleeding disorders
Barker H. F.	-	An unusual case of acquired giant platelet syndrome with May Hegglin features and Hermansky-Pudlak-like platelets
Barker R. N.	-	The phagocytic capacity of human endothelial cells in culture for apoptotic endothelial cells is inhibited by IgG from patients with anti-phospholipid antibodies
Barnard M. R.	-	GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Barnard D.	-	Development of the Canadian hemophilia outcomes – Kids Life Assessment Tool (CHO-KLAT)
Barnes D.	-	A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer
Barnes C.	-	Reference ranges for hemostatic parameters in children
Barnes T.	-	The effects of folic acid supplements on coagulation status in pregnancy
Baron D. W.	-	Abciximab therapy post elective coronary artery stenting does not prevent a troponin rise mediated by increased levels of platelet P-selectin and platelet-monocyte aggregates
Baronciani L.	-	Expression of a new candidate mutation, G1629R, identified in an Italian patient with type 2A von Willebrand disease
Baronciani L.	-	In vitro expression study of two naturally occurring mutations (D141Y and C275S) of the von Willebrand factor (VWF) proeptide that result in defective multimerization and secretion
Baronciani L.	-	Splice site mutations of the von Willebrand factor gene in patients previously diagnosed with von Willebrand disease type 1
Barone M.	-	Oral anticoagulation telemedicine management system: the MC-SAT project
Baroni M.	-	Impaired prothrombinase activity of Factor X Gly381Asp results in severe familial CRM + FX deficiency
Baroowcliffe T.W.	-	Studies of anti-idiotypic polyclonal antibodies developed against antihuman Factor VIII monoclonal antibodies
Barragan P.	-	Evaluation of aspirin resistance by platelet function analyzer (PFA-100™) in patients with acute coronary syndrome®
	-	A dedicated system for standardized measurement of VASP phosphorylation in blood platelets and detection of thienopyridine resistance
	-	Immuno-phenotypic platelet characteristics distinguish high vs. low risk patients for thrombosis after stent implantation under thienopyridin plus aspirin treatment
	-	Interest of VASP measurement on patients treated by thienopyridines
Barral F.	-	Clinical experience with optional cava filters
Barreira J. L.	-	Association of MTHFR and ACE gene polymorphisms in reflux associated with renal damage
Barreira R.	-	A sporadic case of gray platelet syndrome
Barrett B.	-	An evaluation of existing measurement methods in assessing menstrual blood loss in women with hereditary bleeding disorders
	-	Studies to define the clinical impact of ‘mild’ hemophilia A in a large kindred in Newfoundland and Labrador
Barrett-Bergshoeff M. M.	-	Clot penetration and fibrin binding of amediplase
Barrois D.	-	Safety and efficacy of Fibrogammin P® for the treatment of patients with severe FXIII deficiency
Barronciani L.	-	Mutation analysis in type 1 von Willebrand disease patients entered in the multicenter MCMDM-1VWD study
Barrow R. T.	-	Characterization of high level expression sequence determinants within porcine factor VIII
Barrowcliff T. W.	-	The use of phospholipid-dependent clotting assays to characterize the cell-surface procoagulant activities of T-lymphoblastoid cell lines
	-	Basal levels of phosphatidylserine exposure on the cell-surface of T-lymphoblastoid and monocytoid cells: relationship to Prothrombin and FX activation, and Tissue Factor activity
Barrowcliffe T. W.	-	Inhibitory effects of human anti-factor VIII monoclonal antibodies and their neutralization by respective anti-idiotypic antibodies using Thrombin Generation Test
	-	Variability in factor VIII concentrate measurement: results from SSC Field Collaborative Studies
	-	Promotion of thrombin generation at low FVIII concentrations by FIXa
	-	A multicenter study on the potency estimation of ReFacto
Bartha K.	-	Thrombin receptors on the cells of the blood–brain barrier
Bartok A.	-	High dose of atorvastatin does not effect levels of plasma tissue factor in patients with coronary artery disease
Bartok A.	-	Abciximab reduces monocyte tissue factor after carotid angioplasty and stenting: role of monocyte platelet cross talk in cerebral microembolization
	-	Abciximab reduces monocyte tissue factor after carotid angioplasty and stenting: role of monocyte platelet cross talk in cerebral microembolization
Bartoli M. G.	-	Transdermal hormone replacement therapy does not affect hemostasis and inflammation
Bartowiak J.	-	Biological and pharmacokinetic activity of the new recombinant thrombolytic and anthithrombotic agent RGD SAK-K2-HIR
Baruch D.	-	Activation of pp125FAK by type 2B recombinant von Willebrand factor binding to platelet GPIb at high shear rate occurs independently of aIIb3 engagement
	-	Platelet translocation on von Willebrand factor is inhibited by RGDS peptide at high shear rate
Baruch D.	-	Specific interaction of the proteolytic SPII fragment of von Willebrand factor with fibrin
Barynin Y. A.	-	Role of protein C system in the advancement of activation zone of coagulation: A two-dimensional mathematical model
Barzegar S.	-	Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS)
Basanova A. V.	-	Proposed mechanisms of thrombolytic action of the medicinal leech saliva
Bashford L.	-	Inactivation of non-enveloped viruses by non-ionic detergent and solvent/detergent in the fibrinogen component of fibrin sealant
Basili S.	-	In vivo platelet activation is associated to increased plasma levels of vascular endothelial growth factor – effects of aspirin treatment
	-	Soluble CD40 ligand (sCD40L) plasma levels in nonsmall cell lung cancer
Baskova I. P.	-	Proposed mechanisms of thrombolytic action of the medicinal leech saliva
Baskova I. P.	-	Anti-hemostasis stimulated by the medicinal leech application as a result of mast cells activation by the leech saliva
Basma El Din B.	-	Tissue factor and tissue factor pathway-inhibitor in chronic hepatitis C patients
Bassitt R. P.	-	Factor VII deficiency and stroke: case report
	-	Successful use of Arixtra® in a patient with PNH, Budd–Chiari syndrome and HIT
	-	Inherited prothrombotic risk factors in a Brazilian cohort with CVT
	-	Acquired prothrombotic-associated factors in cerebral venous thrombosis (CVT)
Bassler N.	-	The Jarvik 2000 artificial heart does not affect the activation status of platelets
Bassus S.	-	Thrombin generation in platelet-rich plasma (PRP) is enhanced in patients with metabolic syndrome
	-	Electron microscopy of thrombasthenic platelets after rFVIIa substitution
Bassus S.	-	Using a modified thrombin generation assay for potency assessment of B-domain deleted recombinant factor VIII (ReFacto®)
Basta G.	-	At least two distinct pathways generating reactive oxygen species mediate endothelial VCAM-1 induction by advanced glycation endproducts
Bastajian N.	-	Molecular dissection of the human TAFI promoter
	-	Effect of polymorphisms in the human TAFI 5'-flanking region on TAFI promoter activity
Bastelica D.	-	Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation
Bastians B.	-	The risk of heparin-induced thrombocytopenia and the frequency of heparin-dependent antibodies in neurologic patients treated with unfractionated heparin
Bastien O.	-	Identification and characterisation of MIP-1b and VE-Cadherin as important markers of acute rejection after human heart transplantation
Bastos M.	-	Markers of hypercoagulability in Brazilian patients with DVT undergoing oral anti-coagulation therapy
Basu S.	-	The effects of thalidomide analogues on VEGF and IL-6 production in myeloma and endothelial cell cocultures
Bataga S.	-	Use of recombinant activated factor VII (NovoSeven) in patients with liver cirrhosis
Bates S. M.	-	Management of venous thromboembolism during pregnancy
	-	Levels of D-dimer do not predict deep venous thrombosis in medical–surgical ICU patients
	-	Use of different d-dimer levels to exclude venous thromboembolism depending on clinical pretest probability
Bates S.	-	Ability of d-dimer to reduce the need for diagnostic imaging in patients with suspected pulmonary embolism: A randomized trial
Bath P. M. W.	-	Platelet–leukocyte interactions in the presence of GPIIb-IIIa antagonists, and a combination of aspirin, dipyridamole and AR-C69931
Bath P.	-	The effects of three anti-platelet drugs (aspirin, clopidogrel, dipyridamole) given singly or together on platelet and leukocyte function in healthy subjects and patients with previous ischemic stroke
Batista J. F.	-	Gene transfer of naked plasmid DNA encoding VEGF121 leads to revascularization of ischemic tissue in animal models of vascular diseases
	-	Gene transfer of naked plasmid DNA encoding VEGF121 leads to revascularization of ischemic tissue in animal models of vascular diseases
Batlle J.	-	An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio
	-	Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease
Batlle J.	-	Replacement therapy for surgery and delivery in three patients from a single family with R1374C type 2M von Willebrand disease (VWD): the role of PFA100 monitoring
Battaglioli T.	-	Inherited thrombophilia and hyperhomocysteinemia in upper limb deep vein thrombosis
	-	Embryo implantation after assisted reproductive procedures and maternal thrombophilia
Battaglioli T.	-	Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives
Battaglioli T.	-	Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed with commercial and home made methods
Battaglioli T.	-	High risk of cerebral-vein thrombosis in patients with hyperhomocysteinemia
Battistella P. A.	-	Incidence of recurrent ischemic stroke in children with coagulation abnormalities
Battle J.	-	Mutation analysis in type 1 von Willebrand disease patients entered in the multicenter MCMDM-1VWD study
	-	Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand's disease (VWD): The progress of a European collaboration
	-	Sensitivity and specificity of PFA-100® vs. bleeding time in the diagnosis of type 1 von Willebrand disease (VWD)
	-	Comparison of hemorrhagic symptoms in obligatory carriers of type 1 and type 3 von willebrand disease (VWD): results from a collaborative, international, multicenter study
	-	In vitro expression of 4 novel mutations identified in type 1 von Willebrand disease patients
	-	A new candidate mutation (C1272S) in type 2 A von Willebrand disease (VWD) affecting the disulfide loop responsible for the interaction of von Willebrand factor (VWF) with platelet glycoprotein Ib-IX
	-	Clinical presentation of type 1 von Willebrand disease (VWD) in obligatory carriers: final results from a collaborative, international, multicenter study
	-	Evaluation of a new quantitative, rapid test (VWF-LIA) for the diagnosis of type 1 VWD
Baudo F.	-	Blood glutathione detects pro-oxidant patterns in mild hyperhomocysteinemia associated with atherothrombotic vascular events
	-	Clinical presentation of type 1 von Willebrand disease (VWD) in obligatory carriers: final results from a collaborative, international, multicenter study
Baudo F.	-	Recombinant activated Factor VII (rFVIIa) for the treatment of bleeding secondary to acquired factor VIII inhibitor
Baudo F.	-	Comparison of hemorrhagic symptoms in obligatory carriers of type 1 and type 3 von willebrand disease (VWD): results from a collaborative, international, multicenter study
	-	VWF:RCo assay implementation on automated coagulometer
Baudo F.	-	Perioperative management with low molecular weight heparin (LMWH) of patients (pts) on long-term oral anticoagulant therapy (OAT) undergoing major surgery: a multicenter prospective observational study
Bauer K. A.	-	Persistent biochemical hypercoagulability and risk of death from cancer in middle-aged men
	-	Relevance of venographic distal thrombus assessment in venous thromboembolism (VTE) prophylaxis studies: lessons from the fondaparinux (Arixtra®) database in major orthopedic surgery
	-	Heritability of clotting factors and the prothrombotic state: results from a large thrombophilic pedigree of French Canadian descent with Type I protein C deficiency
	-	Thrombin generation after ischemic stroke: the hemostatic system activation study (HAS)
Bauer K. A.	-	Management of thrombophilia
Bauer K. A.	-	No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study
Bauer E.	-	Treatment of adults with sepsis-induced coagulopathy and purpura fulminans with a plasma-derived protein C concentrate (Ceprotin®)
Bauer K. A.	-	Influence of the duration of fondaparinux prophylaxis in preventing venous thromboembolism (VTE) following major orthopedic surgery
	-	Polymorphisms of the factor VII gene and ischemic stroke in young adults
	-	Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study
Bauersachs R.	-	Use of danaparoid sodium for continuous renal replacement therapy in intensive care patients
	-	Routine homocysteine monitoring: stabilization of blood samples with fluoride
Bauersachs J.	-	Platelet activation and platelet VASP phosphorylation in mice with streptozotocin-induced diabetes mellitus – association with endothelial dysfunction and reduced nitric oxide bioactivity
Bauersachs R.	-	Discontinuation of long-term oral anticoagulation (OAC): effects of concomitant administration of low-molecular weight heparin (LMWH) during the termination period – a prospective study
Bauersachs R.	-	Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia
Bauersachs J.	-	Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and angiotensin-converting enzyme inhibition – role of platelet VASP phosphorylation
Bauersachs R. M.	-	Safe anti-coagulation with danaparoid in pregnancy and lactation
Bauersachs R.	-	Risk factors and long-term follow-up of patients with the immune type of heparin induced thrombocytopenia
	-	The German thrombophilia-registry – first results: Women specific risk factors and venous thrombosis
Bauersachs J.	-	Novel role for the membrane-bound chemokine fractalkine as a pathophysiologically relevant mechanism in platelet activation and adhesion
Bauersachs R.	-	Detection of lupus anticoagulant: development of a new precise, sensitive and specific aPTT-based assay
Bauman M.	-	Very low dose warfarin for primary and secondary prophylaxis in children: a prospective cohort study of 20 children
	-	Reversal of low molecular weight heparin (LMWH) prior to invasive procedures using subcutaneous unfractionated heparin in children with an ongoing high risk for thrombosis
Bauman M. V.	-	Probabilistic modeling of population-based epidemiology and treatment modalities to determine unconstrained factor VIII demand
Bauman M.	-	Vena cava filters in children: review of a single centre clinical experience over 7 years
Bauman M.	-	Reversal of warfarin or low molecular weight heparin (LMWH) using subcutaneous unfractionated heparin (UFH) in pediatric outpatients with an ongoing high risk for thrombosis and requiring invasive procedures: a prospective cohort study of 146 children
Bauters A.	-	Tissue factor predicts long-term outcome after percutaneous coronary revascularization
Bauters C.	-	Tissue factor predicts long-term outcome after percutaneous coronary revascularization
Bavington J.	-	Increased coagulation factor XIII B subunit antigen and factor XIII biotin activity is associated with family history of stroke in South Asians
	-	Increased factor XIII B and decreased factor XIII A subunit antigen levels in insulin resistant South Asian patients with ischaemic stroke
Baxi S. M.	-	The Gas6 receptors Axl, Sky, and Mer function to enhance human platelet degranulation and aggregation
Bayard F.	-	The protective effect of estradiol is dependent on immune system for spontaneous atherosclerosis but not for injury-induced atherosclerosis
Bayry J.	-	Kinetics of hydrolysis by anti-FVIII antibodies in hemophilia A
	-	Perturbations in the blood T-cell repertoire of inhibitor-positive patients with severe hemophilia A
Bazan-Socha S.	-	Novel polymorphic short tandem repeat in the human a2 integrin gene promoter is associated with GPIa/IIa density on the platelet surface
Bazarbachi A.	-	High prevalence of prothrombin G20210A mutation among patients with deep venous thrombosis in Lebanon
Bazzan M.	-	Prolonged APTT children undergoing elective tonsillectomy
	-	Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism
	-	Anti-protein S antibodies in patients with venous and/or arterial thrombosis
	-	A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter
Bdeir K.	-	A novel platelet-specific delivery system for fibrinolytic agents
	-	Regulation of neovascularization by a-defensins: a link between inflammation and angiogenesis
Beardsley D. S.	-	‘Video Grand Rounds’: an assessment of internet based grand rounds to increase collaboration between comprehensive hemophilia treatment centers
Beauchamp N. J.	-	The prevalence of, and molecular defects underlying, inherited Protein S deficiency in the general population
	-	Comparison of cytotrophoblast gene expressed in normal and pre-eclamptic placenta
Beaudin S.	-	Prognostic value of activated protein C levels in patients with severe sepsis
Beaune P. H.	-	Variations of INR and Factor VII Level are linked to Cytochrome P450 2C9 genotype
Beavis J.	-	‘Aspirin resistance’ detected by high shear platelet function testing within the pilot phase of the Oxford Vascular Study (OXVASC)
	-	The PFA-100®: a screening tool for platelet dysfunction – the Oxford experience
Becattini C.	-	Long-term clinical outcome of patients with pulmonary embolism: a prospective, multicenter study
Becattini C.	-	Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism
Becher H.	-	Platelet function under aspirin, clopidogrel and both after ischemic stroke. A case-crossover study
Becker R. C.	-	Effect of the direct factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease
Becker S.	-	F VIII:C, Ristocetin-cofactor and von Willebrand factor in children with venous thrombosis or cerebral infarction
Becker S.	-	Clinical manifestation and therapy in children with hereditary angioedema (HAE) – a prospective follow up
	-	Developing hematopoietic stem cells as targets for gene therapy of hemophilia A
Becker P.	-	The use of the rotational thrombelastograph (ROTEG) in the quantification of the ‘lytic state’ during thrombolytic therapy: a comparative analysis in the subhuman primate
Becker S.	-	Favourable course of hemorrhagic complication in early pregnancy of a patient with congenital afibrinogenemia under replacemant therapy
Becker M.	-	Anti-inflammatory mechanisms of PS3, a new drug candidate with both anti-inflammatory and anti-thrombotic activities
Becker L.	-	A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) assembly
Becker U.	-	Frozen or lyophilized normal plasmas pose a strong bias for reporting PT values
Becker S.	-	Intracellular trafficking of native, full-length, and B-domain-deleted coagulation factor VIII (FVIII) in mammalian cells
Becker R.	-	FXa inhibition in general blood coagulation
Becker C.	-	Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery
Beckmann M. W.	-	High levels of plasma markers of coagulation factors (I, VIII:C, XI, XII), inflammation, and hyperhomocysteinemia are risk determinants of pre-eclampsia and HELLP syndrome
Becquemont L.	-	Variations of INR and Factor VII Level are linked to Cytochrome P450 2C9 genotype
Bedendo S.	-	Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft
	-	Levels of anti-thrombin III activity in the plasma of cynomolgus monkeys after administration of recombinant human anti-thrombin III
Bednarek R.	-	Up-regulation of plasminogen activator inhibitor-1 (PAI-1) by thymosinb 4 in endothelial cells
Beecken W. D.	-	Malignancy and metastasis is not associated with decreased ADAMTS-13 activity in patients with brain tumors and prostate tumors
Beer N.	-	Mechanisms involved in the differential regulation of endothelial cells and lung fibroblasts by the hyaluronan-binding protease
Beer J. H.	-	Blockade of GPIIb/IIIa by abciximab, eptifibatide and tirofiban at high shear results in a differential inhibition of platelet aggregation, platelet microparticle formation and phosphatidylserine exposure
Beevers D. G.	-	Impaired vascular function in hypertensive pregnancy
Beganovic A.	-	Symptomatic plaques of type 2 diabetic patients show more plaque complications but similar expression patterns of markers for coagulation and inflammation compared to nondiabetic controls
Begbie M. E.	-	Carboxy-terminal mutations render heparin cofactor II more susceptible to secretory impairment than equivalent mutations in antithrombin
Begelman S. M.	-	Reteplase and direct thrombin inhibitors: concurrent use for acute thrombotic events in patients with heparin-induced thrombocytopenia
Béguin S.	-	Increased thrombin potential due to acquired activated protein C resistance in patients with lupus anticoagulants
	-	Defective vWF–Fibrin–GPIb interaction causes impaired prothrombin consumption in Bernard–Soulier Syndrome
	-	Exposure of procoagulant phospholipids in blood during exhaustive physical exercise
	-	Thrombinography can differentiate bleeding from nonbleeding patients with prolonged APTT
	-	The calibrated Thrombogram: exact monitoring of thrombin generation in clotting platelet rich- and platelet poor plasma
Beh S. J.	-	Critical lower limb ischemia caused by essential thrombocytosis and successful limb salvage using angiographic-guided intra-arterial thrombolysis with rTPA
Behan M. W. H.	-	P2Y12 antagonists interact with agents that stimulate adenylate cyclase to inhibit calcium mobilization responses in platelets
Behan M.	-	Effects of ADP-antagonists on platelet calcium mobilization in acute coronary syndrome patients
Beijlevelt M.	-	Impact of knowledge of a positive family history on the clinical presentation of hemophilia
Beilin L. J.	-	Prediction and prevention of thrombosis during pregnancy and oestrogen use
Beillat T.	-	The Asp299Gly polymorphism of Toll-like receptor 4 as a genetic risk factor for acute coronary events
Bekcer A.	-	Legg-Perthe's disease and thrombophilia: a causal association?
Belch J. J. F.	-	Soluble P-selectin and P-selectin expression (CD62P) both reflect the same in vivo platelet activation
	-	Increased neutrophil apoptosis in chronic fatigue syndrome
	-	Dark chocolate inhibits platelet aggregation in healthy volunteers
	-	Increased plasma isoprostanes and other markers of oxidative stress in chronic fatigue syndrome
Belkaid I.	-	Successful use of rFVII for an hemorrhagic Port-a-cath insertion in a Fanconi's disease
Bell P. R. F.	-	Prevention of thromboemboli by enhancing fibrinolysis: a possible therapeutic mechanism of action for Dextran-40
Bell R. J.	-	Increased VWF antigen clearance in partial quantitative von Willebrand factor deficiency and reporting of a familial tendency
Bell D.	-	Management of pulmonary embolism: Can we consider outpatient treatment?
Bell P.	-	Hemophilia A: total correction in mice and partial correction in dogs with canine FVIII using a new AAV serotype
Bellinger D. A.	-	Cloning and expression of full-length recombinant porcine von Willebrand factor
Bellissimo D. B.	-	A case of compound type 2N/type 1 von Willebrand disease linked to a novel von Willebrand factor exon 18 mutation A2311G encoding for Met 771 val
Belloni L.	-	1286 prospective consecutive cases of venous thromboembolic disease at the single venous thromboembolic Unit of Reggio Emilia
Bellotti A.	-	Soluble CD40 ligand (sCD40L) plasma levels in nonsmall cell lung cancer
Bellucci S.	-	Defective vWF–Fibrin–GPIb interaction causes impaired prothrombin consumption in Bernard–Soulier Syndrome
Beloqui O.	-	Circulating prostaglandin E2 is associated with high risk of coronary heart disease in asymptomatic subjects: a novel inflammatory marker of subclinical atherosclerosis
Beltrame F.	-	Low vitamin B6, markers of inflammation, and coronary artery disease
Beltrami M.	-	Hyperhomocysteinemia and other thrombophilic factors in Italian patients with inflammatory bowel disease
Beltrán-Miranda C. P.	-	Clinical manifestation of severe hemophilia B ameliorated by Prothrombin 20210A
Belvini D.	-	Molecular genotyping of the Italian cohort of patients with hemophilia B
Belvini D.	-	Intron 1 factor VIII gene inversion in patients with severe hemophilia A
Belvis R.	-	Risk of ischemic stroke (IS) associated with plasma levels of thrombin-activatable inhibtor fibrinolysis (TAFI)
Belzunce M.	-	Pravastatin modulates the cytokine-induced endothelial expression of PGE2: A novel anti-inflammatory mechanism of cholesterol-lowering drugs
	-	The endothelial expression of pai-1 by Angiotensin II is dependent on the 4 g/5 g polymorphism: clinical and therapeutic implications
	-	Proteolytic pattern in advanced atherosclerotic human lesions: relation to vascular bed, plaque features, and cardiovascular risk factors
Bender T.	-	P38 MAP kinase is rapidly phosphorylated via agonist-specific pathways in human and dog platelets, but its activation is not causally linked to secretion
Bender H. G.	-	High levels of plasma markers of coagulation factors (I, VIII:C, XI, XII), inflammation, and hyperhomocysteinemia are risk determinants of pre-eclampsia and HELLP syndrome
Bendit I.	-	Inherited prothrombotic risk factors in a Brazilian cohort with CVT
Benedicto D.	-	Biological effects of sulodexide on hemostatic risk factors of thrombogenesis
	-	Is sulodexide an alternative treatment in the prophylaxis of thromboembolic disease?
Beneke H.	-	Successful treatment with rituximab in a case of relapsed acquired hemophilia
Benessiano J.	-	a2b1 density and a2 polymorphisms in coronary artery disease
Benetucci J. A.	-	Insulin resistance status and truncal fat are important determinants of plasminogen activator inhibitor type-1 (PAI-1) levels in HIV infected patients
Benetucci B. S.	-	Increased levels of endothelial injury marker in close relationship with lipoatrophy in HIV infected patients under high active antiretroviral treatment
Benford K.	-	A type 2A (Group II) von Willebrand disease mutation (Leu1503Glu) associated with a minimal loss of high molecular weight von Willebrand factor (VWF) multimers
	-	The type 1/type 2M von Willebrand disease dilemma: findings from the Canadian Type 1 VWD study
Benhida A.	-	Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor
	-	Deletion of residue Ala2201 in the factor VIII C2 domain impairs FVIII interactions with phospholipids and vWF and results in mild hemophilia A
Beninato L.	-	Effects of HRT with estradiolvalerate 2-mg + levonorgestrel 75 µg (NUVELLE®) on clotting and lipid profile
Benítez H.	-	Clinical manifestation of severe hemophilia B ameliorated by Prothrombin 20210A
	-	Clinical manifestation of severe hemophilia B ameliorated by Prothrombin 20210A
Benjamin R. J.	-	INTERCEPT platelets, treated to inactivate pathogens, maintain hemostasis in thrombocytopenic patients: results of the SPRINT trial
Benli S.	-	Thrombotic risk factors in stroke patients
Bennett B.	-	Thrombolytic properties of normal human neutrophils
Bennett J.	-	Activation of the platelet integrin aIIbb3 by thermodynamic modulation of transmembrane helix associations
Bennett J. S.	-	Intermolecular forces of individual aIIbb3-fibrinogen and aVb3–osteopontin interactions on platelets
Bennett C. E.	-	The influence of metformin on markers of inflammation in subjects with type 2 diabetes mellitus: evidence to support the common soil hypothesis
Bennett B.	-	Plasminogen activators: a feature of normal myeloid differentiation or leukemic transformation?
Benson J.	-	The relationship between genetic variants in peroxisome proliferator-activated receptors and venous thromboembolism in African-Americans and Caucasians
Benson E.	-	Platelet aggregation and ATP release in whole blood for diagnosis of bleeding disorders
	-	Phospholipid-dependent impairment of the inhibitory properties of hirudin: the cause of false-positive assays for lupus anticoagulants (LAs)
Bentancor N.	-	Retrospective study of acquired factor VIII inhibitor
Benz J.	-	The active conformations of Factor VIIa and Factor IXa: biochemical, biophysical, chemical and crystallographic studies
Benz K.	-	Disseminated intravascular coagulation after varicella infection
Benziger L. B.	-	Type 2 M von Willebrand disease due to linked P1266Q and V1279I substitutions in the von Willebrand factor A1 domain
Beran M.	-	The impact of intravenous heparin administration on duration of hospitalization
Beranek M.	-	Risk of venous thromboembolism during pregnancy and puerperium in women with homozygous form of F V Leiden
Berard A.	-	Patients with the post–thrombotic syndrome have worse disease severity and quality of life than patients with primary chronic venous disease
Berardinelli L.	-	Arterio-venous fistula as permanent access for home treatment in children with hemophilia: long-term safety and feasibility
Berdel W. E.	-	Overexpression of basic fibroblast growth factor (bFGF) in the bone marrow of patients with acute myeloid leukemia: a potential role for bFGF as an autocrine growth factor
Bereczky Z.	-	Plasma factor XIII activity, concentration and FXIII-A Val34Leu polymorphism in patients with myocardial infarction and/or coronary sclerosis
Berg S.	-	Studies of blood coagulation and platelet function in thoracic surgery utilizing a point of care instrument, a free oscillation rheometer
Berge J.	-	The thrombin generation test (TGT) may be a predictive parameter for thrombus formation during endovascular embolization of cerebral aneurysms
Berge T.	-	Elevated concentrations of nitrate in plasma from smokers
	-	Prevalence of hyperhomocysteinemia among aluminum industry workers
Berge N.	-	Prevention of wine consumption on thrombosis but not on atherosclerosis in ApoE-/- mice
	-	A comparative pharmacodynamic study of anti-Xa activity to evaluate the accumulation effect of Tinzaparin and Enoxaparin given at prophylactic dose over 8 days in elderly patients with impaired renal function
Bergmann J. - F.	-	A comparative pharmacodynamic study of anti-Xa activity to evaluate the accumulation effect of Tinzaparin and Enoxaparin given at prophylactic dose over 8 days in elderly patients with impaired renal function
Bergmann J. F.	-	d-dimer levels: a prognostic value in patients with chronic atrial fibrillation
Bergmann J. - F.	-	A risk assessment model for identifying medical patients who should receive thromboprophylaxis
Bergmann J. F.	-	Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VII
Bergmann J.F.	-	Use of LMWHs in patients with renal impairment
	-	A multinational observational cohort study in hospitalized medical patients of practices in prevention of venous thromboembolism and clinical outcomes: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE)
Bergmann L.	-	ADAMTS-13 activity and corresponding inhibitor titers during plasma exchange therapy in 13 pts with Thrombotic Thromobcytopenic Purpura (TTP)
Bergmann J. F.	-	Oral anti-coagulation in elderly patients in clinical practice: 187 patients
Bergmeier W.	-	Anti-thrombotic effects of tumor necrosis factor-a
Bergmeier W.	-	Inhibition of metalloproteases during platelet storage leads to better platelet recovery and improved platelet function upon transfusion
Bergqvist D.	-	Prolonged thromboprophylaxis with low molecular weight heparin (tinzaparin) following major general surgery primarily for cancer: An individual patient data meta-analysis
	-	Ximelagatran, the latest advance for oral thromboembolic prophylaxis
	-	Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review
	-	A randomized double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus study
Bergqvist D.	-	Prolonged prophylaxis against VTE with enoxaparin in patients undergoing surgery for malignancy: 1-year survival study
Berkane N.	-	Inherited thrombophilia is not associated with an increased risk of intrauterine fetal death
Berkefeld J.	-	Increased thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae
Berkovskiy A. L.	-	Laboratory (on base coagulological tests) it is latent proceeding hematogenous thrombophilias
	-	Dynamics of changes of parameters of a hemostasis in patients with sepsis
Berkovsky A. L.	-	Dynamics of changes of parameters of a hemostasis in patients with sepsis
Berkowitz S. D.	-	Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR)
Berland Y.	-	The uremic retention solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair in vitro
Berlin G.	-	Effects of anticoagulation, red blood cells and number of platelets on coagulation and clot elasticity measured by free oscillation rheometry
Bermejo E. I.	-	Fibrinolytic activity and response to venous occlusion in activated protein C resistance phenotype
Bermejo E.	-	Flow cytometry analysis of platelet activation throughout normal gestation and puerperium
Bermejo E.	-	Prevalence of haemostatic and fibrinolytic abnormalities in women with unexplained embryofetal losses and vascular obstetric complications
Bermudez M. C.	-	Preparation of prothrombin complex concentrate (PCC) at intermediate scale: first experience in Argentina
Bermudez A.	-	Successful use of recombinant FVIIa (Novoseven) for severe bleeding in a patient undergoing bone marrow transplantation refractory to standard hemostatic support
	-	Recombinant Factor VIIa as hemostatic agent in acquired von Willebrand disease
Bernadi F.	-	Genetic variants of CYP2C9 cytochrome do not account for high intraindividual variability of patients in their response to oral anti-coagulants (OA): a collaborative controlled study
Bernadi M. E.	-	Development, scale up and characterization of the first regional high purity Factor VIII: the Argentinean experience
Bernardi F.	-	Impaired prothrombinase activity of Factor X Gly381Asp results in severe familial CRM + FX deficiency
Bernardi E.	-	Different thromboprophylaxis approaches in patients undergoing knee arthroscopy (KANT study): interim report of prospective randomized study
	-	Atherosclerosis as a potential risk factor of venous thrombosis
Bernardi F.	-	Development of inhibitors against factor VII in patient with severe factor VII deficiency
	-	The Factor V HR2 haplotype and the risk of venous thrombosis: a metanalysis
Bernardi E.	-	The long-term clinical course of acute deep vein thrombosis of the arm: a prospective cohort study
Bernardi E.	-	Below-knee elastic compression stockings for prevention of the post–thrombotic syndrome in patients with proximal-vein thrombosis: a prospective controlled randomized study
Bernardi F.	-	Modulation of factor V levels in plasma by intragenic polymorphisms
	-	Factor VII polymorphisms and the risk of myocardial infarction in coronary atherosclerosis
	-	Heterogeneous molecular pattern of Factor VII deficiency associated to cerebral hemorrhage
Bernardi M. E.	-	Preparation of prothrombin complex concentrate (PCC) at intermediate scale: first experience in Argentina
Bernardi F.	-	Enhanced thrombin generation and mild bleeding tendency in a severely FVII-deficient patient carrying FV Leiden
Bernardo A.	-	Peptides from the C-terminal regions of ADAMTS-13 specifically block cleavage of ultra-large von Willebrand factor multimers on the endothelial surface under flow
Bernasconi S.	-	Thrombophilic screening in patients with paroxysmal nocturnal hemoglobinuria
Bernasconi S.	-	Hemophilia in pediatrics: clinical experience in a single hemophilia center
Bernbeck B.	-	Severe intracranial hemorrhage in a patient with von Willebrand disease type 2B after being hit by a golf ball
Berndt M. C.	-	aIIbb3 activation by botrocetin/vWf is ADP or TXA2 dependent and the resulting aIIbb3 outside-in signaling is the major trigger for subsequent granule release and TXA2 production
	-	Interaction of the glycoprotein (GP) Ib-IX/V complex with the platelet collagen receptor GPVI
	-	Differential role of phosphatidylinositol 3-kinase in glycoprotein Ib-mediated platelet activation
Bernhofer P.	-	Abciximab reduces monocyte tissue factor after carotid angioplasty and stenting: role of monocyte platelet cross talk in cerebral microembolization
	-	Abciximab reduces monocyte tissue factor after carotid angioplasty and stenting: role of monocyte platelet cross talk in cerebral microembolization
Berntorp E.	-	Monitoring the pharmacokinetic of inhibitor-bypassing agents with a new thrombin generation assay
	-	Hand computer and Internet for collection and presentation of patient diary data in a Nordic clinical multicenter safety surveillance study of ReFacto®
	-	Continuing clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in previously treated patients (PTPs)
	-	Global hemostatic tests, protein C and anti-thrombin in the intensive care unit setting; correlations and ability to predict outcome
Berntrop E.	-	Long term prophylaxis in VWD
Berrettini M.	-	Enhanced thrombin generation and mild bleeding tendency in a severely FVII-deficient patient carrying FV Leiden
Berroeta C.	-	a2b1 density and a2 polymorphisms in coronary artery disease
Berry L. R.	-	Binding of heparin to alkaline earth and transition metals
	-	Isoform composition of antithrombin (a-AT vs. b-AT) in a covalent antithrombin-heparin complex
Berry J.	-	The epitope of the CD109 monoclonal antibody 8A3 overlaps with the epitope of Gov antibodies: implications for Gov antibody detection
Berry L. R.	-	Effect of heparin on thrombin generation in factor VIII depleted plasma supplemented with FEIBA or FVIII
	-	Binding of covalent antithrombin–heparin complex to endothelial cells
	-	The effect of age on plasmin generation in the presence of fibrin monomer on endothelium
Berry L. R.	-	Activated protein C generation is greatly decreased in plasma from newborns compared to adults in the presence or absence of endothelium
Berry L. R.	-	Effect of protein binding on the anti-FXa activity of different heparinoids in either adult or newborn plasma
Bersier D. E.	-	Cellulitis and deep vein thrombosis: a controversial association
Bertazzoni G.	-	In vivo platelet activation is associated to increased plasma levels of vascular endothelial growth factor – effects of aspirin treatment
Bertesi M.	-	Reduced platelet sensitivity to nitric oxide donors in patients with a history of preeclampsia
	-	Elevated plasma levels of factor VIII in women with early recurrent miscarriage
Berthet B.	-	Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation
Bertina R. M.	-	Screening for annexin A5 gene mutations and the risk of the C-1T mutation in venous thrombosis and myocardial infarction
	-	The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene reduces the risk of venous thromboembolism in carriers of the factor V Leiden mutation
	-	Functional analysis of the prothrombin (PT) G20210A variation
	-	C-Reactive protein (CRP) is not a strong inducer of tissue factor in human monocytes
	-	Tissue-specific regulation of protein S gene transcription
	-	Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues
	-	C/EBP
	-	Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci
	-	Activated factor V is inactivated by activated protein C in the absence of APC cleavage sites at Arg306, Arg506 and Arg679
	-	The 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR
	-	Identification of transcription factor binding sites for HNF1-alpha, FOXA2, HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer
	-	Characterization of an immunologic polymorphism in the heavy chain of human factor V, due to a dimorphism of residue 79
Bertina R.M.	-	A comparison of assay methods for thrombin activatable fibrinolysis inhibitor (TAFI)
Bertoglio J.	-	Cross-talk between alpha2beta1 integrin and GPVI receptors regulates actin polymerization through Rho GTPase and MAP kinase Erk1/2 signaling pathways in human megakaryocytes
Bertoglio S.	-	A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter
Bertola J. P.	-	Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VII
Bertoldi A.	-	Long-term clinical outcome of patients with pulmonary embolism: a prospective, multicenter study
	-	Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism
Bertomoro A.	-	Interaction of factor VIII and von Willebrand factor investigated in a large cohort of von Willebrand disease patients: evaluation of the type 2N variant prevalence
Bertoni E.	-	Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal transplant recipients
Bertrand E.	-	The uremic retention solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair in vitro
Bertuzzo D.	-	Efficacy of Haemate P in the management of patients with von Willebrand disease undergoing surgery
Best D.	-	Variation of GPVI levels in platelets: relationship to platelet function at high shear
Bethel M.	-	Agreement between FXIII activity assays and calibrator plasma pools: the need for a FXIII reference standard with regulatory recognition
Bett J.N.	-	Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standard dose abciximab therapy during percutaneous coronary intervention
Bettarello G.	-	Role of polymorphonuclear (PMN) leukocyte activation in the formation of PMN-platelet aggregates in Essential Thrombocythemia (ET) and Polycythemia Vera (PV)
Betti I.	-	Rate of adverse events during OAT in patients with mechanical prosthetic heart valves replacement
	-	Hyperhomocysteinemia as a risk factor for TIA and stroke in patients with AF
Betts L.	-	High resolution crystal structures of two variant fibrinogens suggest ‘B:b’ interactions are critical to normal polymerization
Betz C.	-	Use of danaparoid sodium for continuous renal replacement therapy in intensive care patients
	-	ADAMTS-13 activity and corresponding inhibitor titers during plasma exchange therapy in 13 pts with Thrombotic Thromobcytopenic Purpura (TTP)
	-	Rituximab – a challenge for the therapy of inhibitors to factor VIII
Beukenkamp H.	-	Venous thrombosis and APC resistance during hormone treatment in male-to-female transsexuals
Beurrier P.	-	Safety and efficacy of Fibrogammin P® for the treatment of patients with severe FXIII deficiency
Bevers E. M.	-	IgG antiprothrombin antibodies from patients with antiphospholipid syndrome inhibit the inactivation of Factor Va by activated protein C
Beyersdorf F.	-	The Jarvik 2000 artificial heart does not affect the activation status of platelets
Beyersdorff E.	-	Benefit and risk of heparin addition in maintaining peripheral venous catheters in neonates – a prospective, double-blind, placebo-controlled trial
Bezeaud A.	-	Functional characterization of a naturally occurring homozygous Gly25Ser mutation in thrombin B chain
Bhagwat A.	-	Local and clinical factors are the likely cause of venous thrombosis in lower limb arthroplasty
Bhakta V.	-	Alterations to the Leu444 (P1) residue of heparin cofactor II: Similarities and dissimilarities to HCII (L444R)
	-	Effects of full and partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II on the inhibition of thrombin and activated protein C
	-	Carboxy-terminal mutations render heparin cofactor II more susceptible to secretory impairment than equivalent mutations in antithrombin
Bharadia V.	-	D-dimer for the exclusion of acute deep venous thrombosis and pulmonary embolism: a systematic review
Bhatti A.	-	Thrombotic potential may be increased in healthy individuals with a two-generation family history of premature myocardial infarction
Biagini D.	-	Activation of blood coagulation in patients undergoing perioperative blood salvage and reinfusion of no-washed whole blood after total knee arthroplasty
Biagini M. R.	-	Homocysteine plasma levels in primary biliary cirrhosis (PBC)
Bialik A.	-	FXIII promotes endothelial cell migration, proliferation, and inhibits apoptosis
Bialonczyk C.	-	Assessing the risk of recurrence in patients with a first spontaneous venous thromboembolism by use of D-dimer
Bianchini C.	-	A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the @RISTOS project
Biasiolo A.	-	Symptomatic chronic thromboembolic pulmonary hypertension after symptomatic pulmonary embolism: incidence and risk factors: a long-term follow-up study
Bick R.	-	Oral antithrombin agents comprise the regulatory functions of thrombin
	-	Polypharmacologic actions of low-molecular-weight heparins: lessons from clinical trials
	-	Nitric oxide levels are up-regulated in patients with malignancy associated hypercoagulable state
Biddinger R.	-	Platelet microparticles carry CD40 ligand and up-regulate TF and VEGF in endothelial and melanoma cells: possible role in angiogenesis and metastasis
Bidlingmaier C.	-	Factor XIII Val34Leu polymorphism in pediatric thrombophilia evaluation: is there clinical relevance?
Bieche I.	-	Tissue Factor-603 A–G promoter polymorphism is associated with human monocyte constitutive but not with LPS induced gene expression
Biedermann B. C.	-	VCAM-1/VLA-4 up-regulation as a perpetuation loop in patients with chronic graft vs. host disease?
Bieglmayer C.	-	The effect of b-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism
Bieker R.	-	Overexpression of basic fibroblast growth factor (bFGF) in the bone marrow of patients with acute myeloid leukemia: a potential role for bFGF as an autocrine growth factor
Biel R. K.	-	D-dimer for the exclusion of acute deep venous thrombosis and pulmonary embolism: a systematic review
Bielfeld P.	-	High levels of plasma markers of coagulation factors (I, VIII:C, XI, XII), inflammation, and hyperhomocysteinemia are risk determinants of pre-eclampsia and HELLP syndrome
Bienek C.	-	Removal of a BSE-derived agent by ion exchange chromatography used in the manufacture of a high purity factor VIII concentrate
Bienvenu B.	-	Bilateral deep-vein thrombosis and cancer: prospective study of 103 patients
Bierhaus A.	-	Long-term RAGE-mediated NF-kB activation in diabetic neuropathy and its role in loss of pain perception
Bierhaus A.	-	Commercially available protein infusion solutions can be modified by nonenzymatic glycation which causes NFkappaB-dependent expression of procoagulant and inflammatory gene products
Biesemans W.	-	Importance of the mobility of the P' region for conformational and functional changes in PAI-1
Biffoni F.	-	Safety and efficacy of nadroparin for the treatment or prophylaxis of venous thromboembolism in pregnancy
	-	Efficacy of high purity, monoclonal factor IX concentrate for continuous infusion in an hemophilia B patient undergoing orthopedic surgery
	-	Safety, efficiency and dose saving of continuous infusion modality of protein C concentrate in the management of a protein deficient patient submitted to orthopedic surgical procedure
Biggerstaff J. P.	-	Platelet microparticles carry CD40 ligand and up-regulate TF and VEGF in endothelial and melanoma cells: possible role in angiogenesis and metastasis
	-	Quantitative analysis of fibrin deposition in solid tumors: a potential marker for tumor vascular permeability
Bigi R.	-	A new preanalytical procedure using dried blood spot sample for total homocysteine determination
Bigler D.	-	Identification of a Factor IX cleaving protease and efficient reduction in a high purity Factor IX manufacturing process
Biglioli P.	-	Platelet-associated Tissue Factor: modulation of cell surface expression by platelet agonists
	-	Platelet-associated Tissue Factor expression in patients with unstable coronary artery disease
Biguzzi E.	-	Intruterine Growth Restriction (IUGR) and thrombophilic polymorphisms
	-	PROSIT: functional analysis of identified PROS1gene mutations
Biguzzi E.	-	Genetically defined protein S (PS) deficiency is associated with venous thrombosis
Bihoreau N.	-	Comparability study of two purification processes of a plasma-derived anti-thrombin
Bijl M.	-	Arterial thromboembolism (ATE) in patients with systemic lupus erythematosus (SLE): the contribution of inherited thrombophilic risk factors
	-	The contribution of inherited thrombophilic risk factors to venous thromboembolism (VTE) in patients with systemic lupus erythematosus (SLE)
Bijsterveld N.	-	Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
Bijsterveld N. R.	-	Clopidogrel suppresses rebound coagulation after discontinuation of enoxaparin treatment in patients with acute coronary syndromes
Biller R.	-	F VIII:C, Ristocetin-cofactor and von Willebrand factor in children with venous thrombosis or cerebral infarction
	-	Long-term prophylaxis with FEIBA® in patients with high-responding inhibitors
	-	Favourable course of hemorrhagic complication in early pregnancy of a patient with congenital afibrinogenemia under replacemant therapy
Billett H.	-	Factor VII levels, coronary artery disease, and MI
Billett H. H.	-	Is aspirin resistance more common in Black patients?
Billing Clason S.	-	Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial
Bilora F.	-	Atherosclerosis as a potential risk factor of venous thrombosis
Binder B. R.	-	Oxidized phospholipids inhibit action of endotoxin in vitro and in vivo
	-	Oxidized phospholipids induce proatherogenic genes in murine carotid arteries
	-	Oxidized phospholipids induce the human heme oxygenase-1 via CREB: a feedback mechanism in inflammatory disorders
	-	Urokinase receptor (uPAR) regulates integrin redistribution during initial vascular endothelial growth factor (VEGF)-induced endothelial cell migration
Bindini D.	-	Enhanced thrombin generation and mild bleeding tendency in a severely FVII-deficient patient carrying FV Leiden
Binetti B. M.	-	Hyperprothrombinemia is associated with enhanced TAFI-mediated inhibition of fibrinolysis
Bioh D.	-	The impact of intravenous heparin administration on duration of hospitalization
Birenbaum J. A.	-	Drug-dependent antibodies, what binds where?
Birger-Botkin S.	-	A postoperative platelet count threshold contributes to an earlier diagnosis of heparin-induced thrombocytopenia and improved platelet recovery in cardiac surgery patients. The HITME (Heparin-Induced Thrombocytopenia Multicenter Evaluation) study
Biró É.	-	Soluble tissue factor released by cultured human umbilical vein endothelial cells is microparticle-associated and triggers thrombus formation in vivo
Biro E.	-	Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner
Bishop P. D.	-	Agreement between FXIII activity assays and calibrator plasma pools: the need for a FXIII reference standard with regulatory recognition
	-	CTRP1 – a vascular wall protein that can prevent platelet thrombosis without causing bleeding
	-	Cross–species interactions of FXIII and fibrinogen
Bishop P.	-	Recombinant human Factor XIII decreases gut ischemia reperfusion injury in the rat
Bishop P.D.	-	A randomized, double-blind, placebo-controlled study of the safety and pharmacokinetics of a single dose of recombinant Factor XIII in healthy volunteers
Bissery A.	-	Bilateral deep-vein thrombosis and cancer: prospective study of 103 patients
	-	Factor II 20210 G-A but not Factor V Arg506Gln gene polymorphism is associated with peripheral arterial disease in a case-control study
Bisson R.	-	Contemporary total hip and knee replacement in A patients with haemophilia and high titre of inhibitors to FVIII by using recombinant FVIIa (novoseven) continuous infusion
Bitsadze V. O.	-	A case of pregnancy and labor management in patient with recurrent thromboses and multigenic thrombophilia
	-	A case of catastrophic anti-phospholipid syndrome in pregnant woman with eclampsia
	-	Prophylaxis of main obstetric complications in pregnant women with anti-phospholipid syndrome and genetic forms of thrombophilia
Bizadze V. O.	-	Changes in hemostatic system in oncogynecologic patients
Bizzoni L.	-	Hemophilia in pediatrics: clinical experience in a single hemophilia center
Bjarnason H.	-	Combined mechanical and pharmacologic thrombolysis for ilio-femoral deep venous thrombosis. Single center short-term outcomes
Bjork I.	-	Anti-thrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and conformational activation
Bjorkman J. A.	-	Coronary t-PA release is triggered by cardiac sympathetic nerve stimulation
Bjornson E.	-	Development of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM)
Blackburn J. C.	-	Factors that influence the prescribing of low-molecular-weight heparins (LMWHs) in community hospitals: opinions of physicians, clinical pharmacists, and formulary committee members
Blajchman M. A.	-	Fibrinolysis within the procoagulant VX-2 tumor of rabbit lungs in vivo: Anti-angiogenic behavior of fibrin(ogen) degradation products
Blajchman M. A.	-	Substitutes and alternatives to platelet transfusions in thromocytopenic patients
Blanchette P.	-	Patterns of factor prophylaxis in the Canadian hemophilia A population
Blanchette V.	-	Patterns of factor prophylaxis in the Canadian hemophilia A population
Blanchette V. S.	-	Underlying platelet function disorders and von Willebrand disease in children with epistaxis or menorrhagia
Blanchette M.	-	Central venous catheter (CVC) related thrombosis in boys with hemophilia
Blanchette V. S.	-	Central venous catheter-related thrombosis presenting as SVC syndrome in a hemophiliac with inhibitors
	-	Triple heterozygosity in the alphaIIb gene of a patient with Glanzmann thrombasthenia and platelets with a low alphaIIbbeta3 content
	-	Stability of dilutions of the recombinant factor VIII Kogenate FS stored in syringes
Blanchette V.	-	Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients (PTPs)
Blanchette V. S.	-	Development of the Canadian hemophilia outcomes – Kids Life Assessment Tool (CHO-KLAT)
Blanchette V.	-	Evaluation of rAHF-PFM in pediatric and previously untreated patients
	-	Hemophilia care in the new millenium: cost versus benefit
Blanchette V. S.	-	Final results from the Canadian hemophilia dose escalation prophylaxis trial
Blanco A. N.	-	Fibrinolytic activity and response to venous occlusion in activated protein C resistance phenotype
	-	Platelet von Willebrand factor antigen (VWF:Ag-i) in patients with mucocutaneous bleeding tendency and normal von Willebrand factor (VWF) plasma levels
	-	Cysteine–homocysteine ratio in patients with C677T mutation of the MTHFR gene
	-	Influence of factor VIII (fVIII) levels in patients treated with DDAVP on the activated protein C resistance (APCR)
Blanco A.	-	Behaviour of the protein C (PC)/protein S (PS) ratio in patients with thrombosis
Blanco A. N.	-	Incidence of major hemorrhages related to surgery in type 1 von Willebrand's disease patients
	-	Anti-phospholipid antibodies and hyperhomocysteinemia: response to therapy with folic acid
	-	Effects of factor VIII (fVIII) levels and activated partial thromboplastin time (aPTT) in activated protein C resistance (APC-R) ratio using two different methods
Blanco-Vaca F.	-	A quantitative trait locus on chromosome 11 is the major genetic determinant of homocysteine plasma levels. Results from the GAIT Project
Blanga J. D.	-	The role of spiral CT in alternative diagnosis in patients with clinical suspicion of pulmonary embolism
Blangero J.	-	Genetic dissection of thrombin-activatable fibrinolysis inhibitor (TAFI)
	-	A genome-wide scan for genetic loci influencing levels of thrombin-activatable fibrinolysis inhibitor (TAFI)
	-	Functional resequencing of the factor IX (f-IX) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-IX activity levels in the GAIT project
Blangero J.	-	Novel family based approaches to genetic risk in thrombosis
Blangero J.	-	A quantitative trait locus on chromosome 11 is the major genetic determinant of homocysteine plasma levels. Results from the GAIT Project
	-	Functional re-sequencing of the factor VIII (f-VIII) gene: identifying quantitative trait nucleotides (QTNs) underlying the variation in plasma f-VIII activity levels in the Gait Project
	-	Genetic coregulation of C4b-binding protein (C4BP) and free Protein S plasma levels: a link between complement and hemostasis
	-	Factor VII plasma levels and the F7 structural gene: complete dissection of a human quantitative trait locus
	-	Heritability of plasma antiphospholipid antibodies
Blann A.	-	Increased platelet adhesion in metastatic cancer
	-	Platelet activation and morphologic changes in hypertension
Blann A.	-	Increased plasma tissue factor predicts adverse outcome in chronic heart failure
Blann A.	-	Endothelial damage in congestive heart failure (CHF): relationship between circulating endothelial cells (CECs) and von Willebrand factor (vWf)
	-	Which is the ideal plasma marker of endothelial damage/dysfunction in atrial fibrillation? A comparison of von Willebrand factor, E-selectin and soluble thrombomodulin
Blann A.	-	Impaired vascular function in hypertensive pregnancy
	-	Markers of inflammation, coagulation, endothelial damage and platelet activation in chronic renal disease
Blann A.	-	Platelet, coagulation and endothelial markers in primary thrombocythaemia
	-	Platelet P-selectin and target organ damage in hypertension
	-	Plasma P selectin must be measured in a citrated sample, not in serum
Blasi I.	-	Elevated plasma levels of factor VIII in women with early recurrent miscarriage
	-	Reduced platelet sensitivity to nitric oxide donors in patients with a history of preeclampsia
Blatny J.	-	Multi-diagnostic retrospective study of risk factors of thrombosis in children with cancer – is there a space for multivariate predictive modeling?
	-	rFVIIa NovoSeven®– Hemostatic agent not only for hemophiliacs
Blatt P.	-	A phase I/II trial of AAV-mediated, liver-directed gene transfer for hemophilia B
Blazeková A.	-	Is infection a risk factor of acute ischemic stroke?
Blessing K.	-	Insufficient F IX-recovery after treatment with recombinant F IX compared to plasma-derived F IX
Blinc A.	-	Shear rate of plasma flow and fibrin specificity of thrombolytic agent promote thrombolysis of nonretracted and retracted whole blood clots – a MRI study in vitro
	-	Comparison of magnetic resonance characteristics of the vessel wall between patients with classic and dilatative atherosclerosis
Blinov M. N.	-	Venous thromboembolism in North-western Russia and genetic polymorphisms
	-	The prevalence of polymorphism PlA2 of platelet glycoprotein IIb-IIIa in the population of North-west Russia
	-	Different risk of pulmonary embolism development in patients with deep-vein thrombosis from North-Western Russia having either factor V Leiden or prothrombin G20210A mutation
Bloem H. L.	-	The role of spiral CT in alternative diagnosis in patients with clinical suspicion of pulmonary embolism
Blois S.	-	Hypercoagulability in sickle cell disease: increased monocyte tissue factor expression and increased erythrocyte microparticles expressing phosphatidyl serine
Blom H. J.	-	Effect of the methionine synthase reductase A66G polymorphism on total homocysteine levels and venous thrombosis risk
	-	Hyperhomocysteinemia: risk factor or consequence of venous thrombosis?
	-	Homocysteine lowering by B vitamins and the prevention of secondary deep-vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial
	-	Influence of vitamin supplementation on homocysteine and cysteine concentrations in blood
Blom J. W.	-	Risk of venous thrombosis for patients with various malignancies and with factor V Leiden or the prothrombin 20210 A mutation: the MEGA case–control study
Blom M. B. A. J.	-	Is isolated postmethionine-load hyperhomocysteinemia a separate risk factor for venous thrombosis?
Blom H. J.	-	Elevated plasma cysteine concentration as a risk factor for venous thrombosis
	-	Effects of genes and environmental factors on homocysteine level
	-	Contribution of genetic factors to mild hyperhomocysteinemia
Blombäck M.	-	Improvements in flow measurements of fibrin network permeation in plasma or purified fibrinogen-thrombin system
Blomback M.	-	Clinical presentation of type 1 von Willebrand disease (VWD) in obligatory carriers: final results from a collaborative, international, multicenter study
Blombäck M.	-	Determination of overall hemostasis potential in different coagulation factors deficient plasma and in plasma samples from patients with hemophilia A and B
	-	Determination of the different forms of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with hemophilia A, hemophilia B and von Willebrand disease
	-	Thrombin activatable fibrinolysis inhibitor (TAFI) and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications
Blomback M.	-	Comparison of hemorrhagic symptoms in obligatory carriers of type 1 and type 3 von willebrand disease (VWD): results from a collaborative, international, multicenter study
Blombäck M.	-	Overall hemostasis and thrombin activatable fibrinolysis inhibitor (TAFI) – dependent fibrinolysis in patients treated with the novel oral thrombin inhibitor – ximelagatran
Bloom S.	-	Randomized trial of tinzaparin, a low molecular weight heparin (LMWH) vs. placebo in the treatment of mild-to-moderately active ulcerative colitis
Blough D.	-	Clinical outcomes and medical resource utilization in patients with and without malignancy treated with warfarin
Blumenberg D.	-	Why did rFVIIa have no effect in post delivery bleeding? – a case-report
Blumenfeld Z.	-	Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study
	-	Modulation of systemic and placental hemostatic mechanisms by enoxaparin in women with gestational vascular complications
Boadas A.	-	Factor XI deficiency in Mestizo Venezuelan population
Bobe R.	-	Evidence for extracellular signal-regulated kinase 1/2 activation by thrombin that is independent on epidermal growth factor receptor transactivation in vascular smooth muscle cells
Bobrovitch B.	-	Influence of monocyte on lymphocyte-platelet adhesion
Bobrovnik S. A.	-	Some aspects of human immunity against heat shock proteins 60/65
Bobrovnik S.	-	Ischemia/reperfusion induces binding of circulated immunoglobulins to the blood vessels in vivo
Boca M.	-	Serum homocysteine in chronic liver diseases – risk factor for thrombosis or protection against thrombosis?
Bocassi A. R.	-	Increased levels of endothelial injury marker in close relationship with lipoatrophy in HIV infected patients under high active antiretroviral treatment
	-	Insulin resistance status and truncal fat are important determinants of plasminogen activator inhibitor type-1 (PAI-1) levels in HIV infected patients
Bocassi A.	-	Differences in Th1- and Th2-like cytokine patterns between patients with antiphospholipid syndrome and with lepromatous leprosy-related aPL
Boccalon H.	-	Bilateral deep-vein thrombosis and cancer: prospective study of 103 patients
Bochkov V.	-	Oxidized phospholipids induce the human heme oxygenase-1 via CREB: a feedback mechanism in inflammatory disorders
Bochkov V. N.	-	Oxidized phospholipids inhibit action of endotoxin in vitro and in vivo
Bock S. C.	-	Anti-thrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and conformational activation
Böck M.	-	Factor V Leiden mutation (FV:Q506): A new functional screening assay with 100% specificity and sensitivity
Bock P. E.	-	Mechanisms of conformational activation of prothrombin by staphylocoagulase and fibrinogen substrate recognition
Bock S. C.	-	Inflammatory modulation of alveolar coagulation inhibition in a mouse model of acute respiratory distress syndrome (ARDS)
Böck M.	-	cGMP regulates thrombopoietin-induced CD34+ human stem cell proliferation and differentiation into megakaryocytes
Boda Z.	-	Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding
	-	The role of platelet concentrate in the treatment of von Willebrand's disease
Boda Z.	-	Anti-phospholipid syndrome during pregnancy: only the high-dose of LMWH thromboprophylaxis is successful
Bodamer I.	-	Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery
Bode C.	-	Human, conformation-specific, anti-GPIIb/IIIa (aIIbb3) single-chain antibodies generated by differential phage-display: a new generation of platelet inhibitors specific for the activated GPIIb/IIIa receptor?
Bode W.	-	Mechanisms of conformational activation of prothrombin by staphylocoagulase and fibrinogen substrate recognition
Bode A. P.	-	The development of pro-hemostatic lyophilized platelets with minimized risk for intravascular coagulation
Bode C.	-	The Jarvik 2000 artificial heart does not affect the activation status of platelets
	-	Construction and characterization of a new recombinant plasminogen activator composed of an antifibrin single-chain antibody and a low molecular weight form single-chain urokinase
	-	Integrin aVb3 dependent adhesion and spreading under shear stress is particular dependent on the two phenylalanines in the highly conserved GFFKR-region
	-	Integrin aVb3 dependent adhesion and spreading under shear stress is particular dependent on the two phenylalanines in the highly conserved GFFKR-region
Bodin S.	-	Lipid rafts in platelet activation processes
Boehlen F.	-	Aspirin inhibits VCAM-1 expression induced by antiphospholipid antibodies
Boehncke W. H.	-	P-selectin-dependent lung colonization of melanoma cells is targeted by heparin treatment
Boertjes R. C.	-	Exposure of a binding site for the low-density lipoprotein receptor-related protein (LRP) upon activation of factor V
Boerwinkle E.	-	Coexistence of multiple hemostatic genetic risk factors does not increase risk of coronary heart disease: The ARIC Study results
Boffa M. C.	-	European forum on antiphospholipid antibodies standardization group: results of the 2nd round on antibeta2glycoprotein I home-made assays
Boffa M. B.	-	Polymorphisms in the 3'-untranslated region of the TAFI mRNA modulate TAFI gene expression through control of mRNA stability
	-	Effect of polymorphisms in the human TAFI 5'-flanking region on TAFI promoter activity
	-	Molecular dissection of the human TAFI promoter
Bohling T.	-	PECAM-1 expression in adherent platelets differs from that of thrombi during human microvascular anastomosis
Böhm M.	-	Multicenter comparison of assays for von Willebrand factor-cleaving protease (ADAMTS13) activity
Böhm M.	-	ADAMTS-13 activity and corresponding inhibitor titers during plasma exchange therapy in 13 pts with Thrombotic Thromobcytopenic Purpura (TTP)
Böhm M.	-	Increased thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae
	-	The risk of postoperative hemorrhage after intracranial surgery following early Nadroparin administration – results of a prospective study
Böhm M.	-	Mild ADAMTS-13 deficiency in patients with ischemic stroke
	-	Malignancy and metastasis is not associated with decreased ADAMTS-13 activity in patients with brain tumors and prostate tumors
Bohn R.	-	Safety and Pharmacoeconomic Aspects
	-	Economic evaluation in hemophilia care
Bohner J.	-	Discrepancies in potency assessment of B-domain deleted recombinant factor VIII among different one-stage factor VIII clotting assays
Böing A. N.	-	Subpopulations of tissue factor-exposing microparticles from platelets and T-cells colocalize leukocytic antigens in uncomplicated human type 2 diabetes
Boinot C.	-	Recurrent thrombosis in a young patient with a left-sided inferior vena cava and factor V Leiden and prothrombin 20210A
Boissel J.	-	A systematic review of the accuracy of ultrasound in the diagnosis of asymptomatic deep venous thrombosis: preliminary results
Boissonnat P.	-	Identification and characterisation of MIP-1b and VE-Cadherin as important markers of acute rejection after human heart transplantation
Bokarev I. N.	-	The role of thrombophilias in the origin of cerebrovascular accidents at the patients with Atrial Fibrillation
Bokarev I.	-	The role of thrombophilia in the development of atherothrombosis in diabetes mellitus
	-	Advantage of the ‘Quick’ thrombolysis by streptokinase (SK)
Bokarev I.	-	Complex of Glycoprotein IIb/IIIa – von Willebrand factor (GP IIb/IIIa-vWF) in blood of patients with ischemic heart disease
Boldrin M.	-	Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft
	-	Levels of anti-thrombin III activity in the plasma of cynomolgus monkeys after administration of recombinant human anti-thrombin III
Bolis G.	-	A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the @RISTOS project
Bolliger-Stucki B.	-	High resolution crystal structures of two variant fibrinogens suggest ‘B:b’ interactions are critical to normal polymerization
Bolton-Maggs P.	-	Severe thrombophilia in two brothers due to novel combination of mutations in factor V gene producing quantitative deficiency (Glu119Term) and decreased sensitivity to activated protein C due to a novel glycosylation site (Ile359Thr-FV Liverpool)
Bolton-Maggs P.	-	Identification of six novel mutations in families with type 3 von Willebrand disease
Bolton-Maggs P.	-	Eleven novel mutations in non-Jewish factor XI deficient kindreds detected by SSCP with heteroduplex analysis followed by sequencing
Bolton-Maggs P. H. B.	-	Congenital afibrinogenemia: expression and analysis of novel mutations affecting fibrinogen assembly or secretion
Bolton-Maggs P. H. B.	-	Sibling stem cell transplant to cure Bernard Soulier Syndrome
Bolton-Maggs P. H. B.	-	Functional characterization of recombinant Factor V Liverpool: Ile350Thr, a novel mutation associated with thrombosis
Bolton-Maggs P.	-	Thromboembolism in childhood: a prospective 2 years study in the United Kingdom (February 2001 – February 2003)
Bombeli T.	-	Factor V Leiden mutation (FV:Q506): A new functional screening assay with 100% specificity and sensitivity
Bona R.	-	A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy
Bonar R.	-	Laboratory diagnosis of von Willebrand Disorder: current and past practice in Australasia
	-	Laboratory assessment of acquired thrombophilia: current and past experience in Australasia with lupus anticoagulant (LA) and anti-cardiolipin antibody (ACA) testing
	-	Laboratory diagnosis of congenital thrombophilia: current and past practice in Australia
Boncler M. A.	-	Platelet resistance to aspirin is associated with increased membrane lipid cholesterol
Bond S.	-	Evaluation of a clinical algorithm in nurse led DVT management to identify underlying malignancy
Bond S.	-	Management of pulmonary embolism: Can we consider outpatient treatment?
Bondarenko T.	-	Correlation between endothelial haemostatic markers in patients with coronary heart disease
Bonduel M.	-	Biological and clinical DDAVP response in children with von Willebrand disease (VWD)
	-	Cerebral sinovenous thrombosis (SVT) in children: a prospective 10-year registry in Argentina
	-	Arterial ischemic stroke (AIS) in children: a prospective 10-year registry in Argentina
	-	Venous thromboembolism (VTE) in children: A prospective 10-year registry in Argentina
Boneu B.	-	Shedding of active tissue factor (TF) by rat aortic smooth muscle cells (SMCs) undergoing apoptosis
	-	In terms of clinical impact, thromboplastins with an ISI close to 1 yield better results than thromboplastins with an ISI close to 2, in an external quality control campaign
Bonifer C.	-	Human endothelial cell protein C receptor (EPCR) expression: role of proximal and distal 5'-gene regulatory elements
Bonilla-Escobedo L.	-	Ability of d-dimer to reduce the need for diagnostic imaging in patients with suspected pulmonary embolism: A randomized trial
Bonizzoni E.	-	A clinical outcome-based prospective study on venous thromboembolism in cancer surgery: the @RISTOS project
Bonnefond M.	-	Comparability study of two purification processes of a plasma-derived anti-thrombin
Bonnefoy A.	-	Platelet recruitment in vivo to injured blood vessels is not prevented by GPIIb/IIIa antagonism
	-	Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype
	-	Role of the affinity state of the a IIbb 3 receptor for fibrinogen in the formation and reversibility of model particle and platelet aggregation in shear
Bonner L.	-	Venous thrombo-embolism in the black population
	-	Elevated factor VIIIC level is a major risk factor for venous thrombo-embolism in the black population
Bono F.	-	Effect of anticoagulants with various modes of action on thrombin generation in plasma of mice with targeted Arg47-to-Cys mutation of the heparin-binding domain of antithrombin
	-	Antithrombin-mediated inhibition of factor IXa by synthetic oligosaccharides
Boomsma F.	-	Brain natriuretic peptide (BNP) as a predictor of adverse outcome in patients with pulmonary embolism
Boon D.	-	Characterization of a lupus anticoagulant positive monoclonal antibody against human prothrombin
Boose J. A.	-	Prions are removed from equipment used in the production of plasma derivatives by standard cleaning procedures
Booth N. A.	-	The role of TAFIa in relation to serpin inhibitors of fibrinolysis
	-	Thrombolytic properties of normal human neutrophils
Booth J.	-	Application of a novel polypeptide affinity ligand for purification of recombinant FVIII
Booth N. A.	-	Evidence of transient endothelial activation in patients in sinus rhythm after electrical cardioversion of persistent atrial fibrillation
	-	TAFI is cross-linked by its activation peptide to sites on fibrin(ogen) distinct from other inhibitors of fibrinolysis
	-	The C-terminus of a 2-anti-plasmin: effect on fibrinolysis
Boothby M.	-	The influence of metformin on markers of inflammation in subjects with type 2 diabetes mellitus: evidence to support the common soil hypothesis
Borawski J.	-	Induction of serum hepatocyte growth factor/activin/follistatin system during enoxaparin-anti-coagulated hemodialysis
Borawski J.	-	Relation between circulating endothelial markers and anti-coagulation with different heparins in hemodialysis patients: a prospective study
Bordet J.	-	Deletion of residue Ala2201 in the factor VIII C2 domain impairs FVIII interactions with phospholipids and vWF and results in mild hemophilia A
Bordet J. C.	-	In vitro flow cytometry and functional testing of fresh and cryopreserved platelets
	-	Thrombin generation in von Willebrand diseases
Bordet J. C.	-	Determination of effective concentrations of recombinant factor VIIa (rFVIIa) for Glanzmann thrombasthenia patients by using thrombin generation in platelet-rich plasma (PRP) and platelet-poor plasma (PPP)
Bordet J-C.	-	Monitoring the pharmacokinetic of inhibitor-bypassing agents with a new thrombin generation assay
Borel Derlon A.	-	Acquired von Willebrand Syndrome: four cases associated with monoclonal gammopathy
Borel-Derlon A.	-	Efficacy and safety of the first nanofiltered plasma-derived FVIII (FACTANE®) in previously treated haemophilia A patients
	-	Comparison of FVIII levels as venous thrombosis risk factor measured by a chromogenic and a coagulant assay
Borell M.	-	Genetic dissection of thrombin-activatable fibrinolysis inhibitor (TAFI)
Borensztajn K.	-	Functional consequences of a factor VII gene donor splice site mutation causing a lethal factor VII deficiency: regulation in the splice site selection
Borg J.-Y	-	Thrombophilic risk factors and idiopathic sudden sensorineural hearing loss
Borg J.-Y.	-	Frequency and effects of cytochrome P450 2C9 polymorphisms in 61 patients treated by warfarin
Borg J.	-	Prethrombotic biological markers in congenital thrombophilic patients. Preliminary results of a randomized long-term secondary prophylaxis study using warfarin and comparing two INR target ranges
Borg J.-Y.	-	Protein C promoter polymorphisms are potential additional risk factors for cerebral venous thrombosis
Borg J. Y.	-	Multicenter evaluation of a new polymer tube (Vacuette Sandwich) for coagulation testing. Effect on routine coagulation tests and on plasma levels of markers of coagulation activation
	-	Safety and efficacy of Fibrogammin P® for the treatment of patients with severe FXIII deficiency
Borggrefe M.	-	Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotregocin alfa (activated)
	-	Drotrecogin alfa (activated) inhibits degradation of cytokine-mRNA in an endothelial model of inflammation
	-	TIMP-1, TIMP-2 and MMP-9 as prognostic markers for clinical outcome in sepsis
	-	The impact of factor V Leiden on the endothelial cytokine response to coagulation activation modulated by drotrecogin alfa (activated)
	-	MCP-1 as early marker for cell activation in septic patients
Borkenstein M.	-	Hemostatic risk factors, metabolic control, and microalbuminuria in diabetes mellitus type 1
Borley J.	-	Prophylaxis against venous thromboembolism
Borrel M.	-	Risk of ischemic stroke (IS) associated with plasma levels of thrombin-activatable inhibtor fibrinolysis (TAFI)
Borrell M.	-	The 46C®T polymorphism in the F12 gene as a risk factor for venous thrombosis: association after linkage analysis
	-	Heritability of plasma antiphospholipid antibodies
Borris L.	-	A new, noninvasive test for rapid detection of coagulation activation
Borris L. C.	-	A comparison of survival rates at 8–10 years for hip-fracture patients given thromboprophylaxis with enoxaparin vs. unfractionated heparin
Borroni L.	-	VWF:RCo assay implementation on automated coagulometer
Borsini W.	-	High plasma homocysteine concentrations in cerebrovascular patients with Fabry disease
Bortoluzzi C.	-	Venice DVT
Bos G. M. J.	-	Elevated plasma cysteine concentration as a risk factor for venous thrombosis
	-	Homocysteine lowering by B vitamins and the prevention of secondary deep-vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial
Bos M. H. A.	-	Exposure of a binding site for the low-density lipoprotein receptor-related protein (LRP) upon activation of factor V
Bos G. M. J.	-	Is isolated postmethionine-load hyperhomocysteinemia a separate risk factor for venous thrombosis?
Bosch N.	-	Factor XI deficiency in Mestizo Venezuelan population
	-	Acquired platelet dysfunction with eosinophilia in children: A tropical disease present in Venezuela
Boschetti E.	-	A comparison between routine plasma INRs and fingerstick whole blood INRs determinations, using three portable self-testing devices (Coagucheck®, Pro-Time®, Gem-PLC®) and a near-patient whole blood device (Thrombotrack®)
	-	Management of oral anticoagulant therapy with Thrombotest® using a whole blood testing device (Thrombotrack®) in comparison to routine laboratory PT
Boshkov L. K.	-	Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery: a likely under-recognized complication with significant morbidity and mortality: report of 4 sequential cases
Boshkov L. K.	-	Inhibition of coagulation and thrombin-mediated platelet aggregation by plasmin-cleaved fibrinogen g'-chain carboxyl terminal peptide
Boshkov L. K.	-	Report of argatroban infusions for heparin-induced thrombocytopenia (HIT) diagnosed by functional assay in 2 congenital cardiac surgery patients, a neonate and a 5-month old
Boskovic D.	-	Equilibrium binding measurements of the exosite-dependent interactions of substrates or product with the prothrombinase complex
Bosman M. J. C.	-	The effect of refined and red palm olein compared to sunflower oil on lipids and homeostatic factors in hyperfibrinogenemic patients
Bosman R. J.	-	Lepirudin anti-coagulation in critically ill patients with (suspected) heparin-induced thrombocytopenia and thrombosis
Bosson J. L.	-	A prospective randomized study to assess the usefulness of venous compression ultrasonography (CUS) and plasma d-dimer (DD) assay in the decision to discontinue treatment with a vitamin K antagonist (VKA) after an acute deep-vein thrombosis (DVT)
Bossone A.	-	FV plasma levels and the activated protein C resistance phenotype are modulated by the FV gene Asp79His polymorphism in presence of the FV Leiden mutation
Bossuyt P. M. M.	-	The balance between the benefits and risks of treatment with vitamin K antagonists as perceived by patients
Bossuyt P. M.	-	The optimal duration of treatment with vitamin K antagonists in patients with a first episode of venous thromboembolism: a decision analytic approach
Bossuyt P. M. M.	-	Patients' valuation of outcomes after venous thromboembolism
	-	Physicians' interpretation of ventilation-perfusion lung scans
Bostock J. A.	-	The influence of metformin on markers of inflammation in subjects with type 2 diabetes mellitus: evidence to support the common soil hypothesis
Botchkov V.	-	Oxidized phospholipids induce proatherogenic genes in murine carotid arteries
Botella C.	-	Prospective study of the risk factors for the development of post–thrombotic syndrome after proximal deep vein thrombosis
Bottasso B.	-	Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction
	-	Hemostasis and inflammation in advanced heart failure and after successful heart transplantation
Bouchard B. A.	-	How factor VIIa works in hemophilia
Bouchard B. A.	-	Quantification, as well as functional and phenotypic characterization, of baboon platelet- and plasma-derived factor V demonstrate near identity with human factor V pools
	-	Factor V endocytosed and retained by megakaryocytes is specifically proteolytically processed by an intracellular protease to form the platelet-derived factor V pool
Bouchardy I.	-	Congenital afibrinogenemia: expression and analysis of novel mutations affecting fibrinogen assembly or secretion
Bougie D.	-	Drug-dependent antibodies are accompanied by drug-specific antibodies in Quinine-induced immune mediated thrombocytopenia
	-	Drug-dependent antibodies, what binds where?
Boukour S.	-	Platelets endocytosis of HIV and S. aureus is enhanced by activation and occurs in specific compartment, site of subsequent degranulation
Boulanger E.	-	Erythrocytes from diabetic patients adhere to endothelium and potentiate leukocyte adhesion molecule expression
	-	Glycoxidation products and S100 calgranulin binding to RAGE induce tissue factor production
Boulay-Moine D.	-	A dedicated system for standardized measurement of VASP phosphorylation in blood platelets and detection of thienopyridine resistance
Boulogne A.	-	Glycoxidation products and S100 calgranulin binding to RAGE induce tissue factor production
Boulton F.	-	Residual platelet function can be detected in patients on antiplatelet therapy using novel Hemoscope reagents and standard Thrombelastograph® (TEG®)
Bouma B. N.	-	Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
Bouma B. N.	-	Complex formation of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) with fibrin(ogen)
	-	Generation and characterization of a highly stable form of activated TAFI
	-	Oral contraceptives decrease the sensitivity of plasma for the anticoagulant activity of activated protein C (APC) by decreasing plasma glucosylceramide (GlcCer) level
	-	Platelet factor 4 up-regulates protein C activation relative to TAFI activation
Bouma B.	-	Tissue-type plasminogen activator is a multiligand cross-b structure receptor
Bounameaux H.	-	Cellulitis and deep vein thrombosis: a controversial association
Bounameaux H.	-	Clinical usefulness of D-dimer according to clinical probability in patients with suspected pulmonary embolism
	-	Diagnosing pulmonary embolism with clinical assessment, d-dimer, venous ultrasound and helical computed tomography: a multicenter management study
	-	Clinical usefulness of D-dimer in cancer patients with suspected pulmonary embolism
Bourgeot J. P.	-	In vitro flow cytometry and functional testing of fresh and cryopreserved platelets
Bouriachkovskaia L. I.	-	Platelet activity and circulating leukocyte-platelet aggregates can be markers of thrombotic and inflammatory processes in patients with coronary atherosclerosis
Bouriachkovskaia L. I.	-	Leukocyte–platelet interaction: modulation by lipids of different density and inhibition by high dose of catecholamines
Bourre F.	-	Glanzmann thrombasthenia: a study of two Portuguese families and identification of a new homozygous C insertion in exon 10 of the GPIIIa
	-	Triple heterozygosity in the alphaIIb gene of a patient with Glanzmann thrombasthenia and platelets with a low alphaIIbbeta3 content
Bouton M. C.	-	Protease-nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells
Bouton M.C.	-	Thrombin regulates the expression of its cellular inhibitor protease nexin-1 in smooth muscle cells
Bouziane A.	-	Human platelet microparticles shedding is independent of the Cdc42/Rac1/PAK Pathway
Boval B.	-	Lack of correlation between HPA1 polymorphism and ADP induced platelet activation: study of a large cohort of normal subjects
Boval B.	-	Aspirine resistance: a particularly high prevalence in patients after ventricular assist device implantation
Bovenschen N.	-	Cleavage of factor VIII heavy chain by thrombin increases the affinity for low-density lipoprotein receptor-related protein (LRP)
Bovenschen N.	-	Exposure of a binding site for the low-density lipoprotein receptor-related protein (LRP) upon activation of factor V
Bovill E. G.	-	Quality of life and risk perception in a large family with heritable protein C deficiency (IPCI: International Protein C Investigation)
	-	Effect of the direct factor Xa inhibitor, DX-9065a, on thrombin generation in patients with stable coronary artery disease
Bovill E.	-	Lower degree of protein C activation in protein C deficient individuals of a large kindred with type I PC deficiency, as measured by the level of APC-PCI complex
	-	Asymptomatic venous thrombosis is a frequent event in protein C deficiency: a systematic ultrasound assessment of 208 family members with the 3363-C insertion mutation (IPCI: International Protein C Investigation)
Bovill E. G.	-	Questioning the questionnaire: a sensitivity analysis for data collection on venous thrombosis
	-	Heritability of clotting factors and the prothrombotic state: results from a large thrombophilic pedigree of French Canadian descent with Type I protein C deficiency
Bowden C.	-	Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) is more effective than oral anticoagulant (OA) therapy in cancer patients with venous thromboembolism (VTE)
	-	Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with nonmetastatic malignancy and venous thromboembolism (VTE)
Bowler R.	-	Co-localization of c-AMP-dependent PKA with eNOS in endothelial cell junctions: a clue for regulated NO production
Bowles L.	-	Associations of hemostatic variables with changes in anthropometric measures and metabolic variables in the morbidly obese
Bowyer A. E.	-	The effect of two novel plastic citrate tubes (BD Vacutainer Plus): Results in normal subjects and subjects undergoing Unfractionated heparin therapy
Bowyer A. E.	-	A comparative study of new generation blood sampling tubes for thrombophilia investigations
Bozic M.	-	The frequencies of fibrinogen polymorphisms Taq I, Hae III and Bcl I in patients with deep-vein thrombosis
Bozzini C.	-	Low vitamin B6, markers of inflammation, and coronary artery disease
Bozzini C.	-	Factor VII polymorphisms and the risk of myocardial infarction in coronary atherosclerosis
Bozzini C.	-	Factor VII polymorphisms and the risk of myocardial infarction in coronary atherosclerosis
Bracco G. L.	-	Hemostatic changes in laparoscopic and laparotomic gynecological surgery
Brackman H. H.	-	Epitopes of factor VIII inhibitors analyzed by peptide-arrays
Brackmann H. - H.	-	Mutation profiling in congenital FXIIIA deficiency: detection of 6 novel mutations
Brackmann H. H.	-	Genetic mechanisms underlying the clinical manifestation of hemophilia A in females
Brackmann H.	-	Response to DDAVP in mild/moderate hemophilia A patients according to the underlying factor VIII genotype
Brackmann H. H.	-	Analysis of mRNA in a panel of hemophilia A patients with no detectable mutation in the coding regions of the factor VIII gene
Bradbury M.	-	Evaluation of a clinical algorithm in nurse led DVT management to identify underlying malignancy
Bradford H. N.	-	Domain 5 (D5) of high molecular weight kininogen (HK) induces aggregation of human platelets
Bradley C. S.	-	Development of the Canadian hemophilia outcomes – Kids Life Assessment Tool (CHO-KLAT)
Bragança W. F.	-	Hemostatic parameters in Brazilian asymptomatic carriers of Factor V Leiden, prothrombin (G20210A) and methylenetetrahydrofolate reductase (C677T) mutations
Bragg L.	-	Safety and efficacy of using Low-Molecular-Weight Heparins to bridge patients on long-term warfarin
Braitch M.	-	Soluble endothelial cell markers (sTM, sEPCR and sVWF) in type 2 diabetes
	-	A thrombomodulin (TM) gene promoter variant (TM-33G > A) in type 2 diabetes
Brambilla M.	-	Platelet-associated Tissue Factor: modulation of cell surface expression by platelet agonists
	-	Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte transition into macrophages: critical role for NADPH oxidase
Brancaccio V.	-	Genetically defined protein S (PS) deficiency is associated with venous thrombosis
	-	Women with common prothrombotic mutations are not at higher risk of recurrent intrauterine fetal deaths
	-	Pro-atherogenic role for IgG antioxidised-low-density-lipoprotein-beta-2-glycoprotein-I complex in primary antiphospholipid syndrome
	-	FV plasma levels and the activated protein C resistance phenotype are modulated by the FV gene Asp79His polymorphism in presence of the FV Leiden mutation
	-	Thrombosis do not recur at conventional dose oral anticoagulation (INR 2–3) in primary anti-phospholipid syndrome: comparison with inherited thrombophilia at similar INR
	-	Elevated plasma factor XIII relates to intima media thickness of carotid arteries in primary antiphospholipid syndrome
Brandão M.	-	Coagulation inhibitor monitoring rationale in critical patients with severe sepsis
	-	The prognostic value of platelet count drop in an intensive care unit
Brandao L.	-	Alternate day immune tolerance regimen in severe hemophilia A with high titer inhibitors: a single center's experience
Brandjes D. P. M.	-	Effect of hyperhomocysteinemia on coagulation activation and endothelial cell activation
	-	Coagulation abnormalities in dengue virus infections: more common than currently perceived?
Brandjes D.	-	Levels of endothelial activation markers, D-dimer fragments and pro-inflammatory cytokines and sickle cell disease severity
Brandjes D. P. M.	-	Endothelial cell and monocyte-derived microparticles in severe dengue virus infections
Brandjes D.	-	Elevated steady state serum sVCAM-1 levels occur from an early age in sickle cell patients, but are not related to vasoocclusive crises and acute chest syndrome frequency
Brandjes D. P. M.	-	A two-stage thrombophilia screening protocol: more efficient use of laboratory tests
Brandjes D.	-	Reduced protein C and S activity and sickle cell disease severity
Brandt S.	-	Contrast media and compounds containing iodine prevent fibrin formation
	-	Fibrinogen – a new tool for gene delivery
Branger J.	-	Coagulation factor profiles respond strongly during human endotoxemia
Brant R. F. for the LITE Investigators	-	A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by Warfarin Sodium
Brant R. F.	-	A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer
Brant R.	-	D-dimer for the exclusion of acute deep venous thrombosis and pulmonary embolism: a systematic review
Brass L. F.	-	Bleeding phenotype and decreased viability in rap1b knockout mice
Brass L. F.	-	Contact-dependant signalling during late events of platelet activation
Bray P. F.	-	b3 integrin haplotype influences gene regulation
Bray P.	-	Enhanced sensitivity to thrombin but not thrombin activation peptides in female mouse platelets is induced by low dose estrogen unrelated to ER
Breddin H. K.	-	Transition of treatment with i.v. Argatroban to Phenprocoumon and Acencoumarol
Breddin H.K.	-	Concluding comments
Breddin H.	-	Phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis
Breddin H. K.	-	Effects of argatroban in combination with oral anticoagulation on thrombin generation
	-	Influence of argatroban alone and combined with oral anticoagulants on the assessment of coagulation factors
	-	Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis
	-	Effects of argatroban alone or in combination with phenprocoumon or acenocoumarol on aPTT and ecarin clotting time
Breddin H.K.	-	Is HIT still a medical problem?
Bredeson C. N.	-	The bedside investigation of pulmonary embolism diagnosis (BIOPED) study- a triple blind randomized control trial comparing initial bedside diagnostic tests to standard care (initial V/Q scan) in the investigation of patients with suspected PE
Breillat C.	-	Glanzmann thrombasthenia: a study of two Portuguese families and identification of a new homozygous C insertion in exon 10 of the GPIIIa
	-	Triple heterozygosity in the alphaIIb gene of a patient with Glanzmann thrombasthenia and platelets with a low alphaIIbbeta3 content
Breimo E.	-	The relationship between sh-CRP and reactivity of monocytes and various blood parameters known to play an important role in atherogenesis
	-	Encrypted tissue factor (TF) in circulating human monocytes of healthy individuals
Breindahl M.	-	A comparison of survival rates at 8–10 years for hip-fracture patients given thromboprophylaxis with enoxaparin vs. unfractionated heparin
	-	A new, noninvasive test for rapid detection of coagulation activation
Bremme K.	-	A relationship between SHBG and APCr during OC treatment
Brenkel I.	-	Screening for thrombophilia: an economic assessment
	-	Thrombophilia in pregnancy, combined oral contraceptives and hormone replacement therapy users: a systematic review
	-	The risk of thromboembolism and the effectiveness of prophylactic treatment in thrombophilia patients undergoing major orthopaedic surgery: a systematic review
Brennan M.	-	Evidence for a serum protein mediating Staphylococcus aureus induced platelet aggregation
Brenner B.	-	Modulation of systemic and placental hemostatic mechanisms by enoxaparin in women with gestational vascular complications
	-	The hemostatic balance between tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in cultures of human primary trophoblasts
	-	Endothelial protein C receptor (EPCR) is expressed in placental villi and cultured syncytiotrophoblasts
	-	Mechanisms for acquired activated Protein C resistance in cancer patients
Brenner B.	-	Efficacy and safety of two doses of enoxaparin in pregnant women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study
Brenninkmeijer B. J.	-	A prospective implementation study of out-patient treatment with subcutaneous low-molecular-weight heparin and oral anti-coagulants in patients with deep venous thrombosis in routine clinical practice
Bressan M. A.	-	Objective assessment of deep vein thrombosis and pulmonary embolism can be deferred without increased risk of thrombosis: a practical approach based on the pretest clinical model, d-dimer and the use of low molecular weight heparins
Bressi C.	-	Thrombin generation assessed as endogenous thrombin potential (ETP) in patients with hyper- or hypo-coagulability. Effects of phospholipids, tissue factor and residual platelets on the measurement performed in platelet-poor and platelet-rich plasma
Bretelle F.	-	Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth retardation
Bretschneider E.	-	Evidence for a functionally active protease-activated receptor-3 in human vascular smooth muscle cells
Breuss J.	-	Urokinase receptor (uPAR) regulates integrin redistribution during initial vascular endothelial growth factor (VEGF)-induced endothelial cell migration
Brezillon C.	-	Prevention of wine consumption on thrombosis but not on atherosclerosis in ApoE-/- mice
Bridey F.	-	Efficacy and safety of the first nanofiltered plasma-derived FVIII (FACTANE®) in previously treated haemophilia A patients
Briedenhann S.	-	The use of the rotational thrombelastograph (ROTEG) in the quantification of the ‘lytic state’ during thrombolytic therapy: a comparative analysis in the subhuman primate
Brieger D.	-	Combination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
	-	Combination therapy with low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
Brien D. F.	-	Polymorphisms in the 3'-untranslated region of the TAFI mRNA modulate TAFI gene expression through control of mRNA stability
Brighton T. A.	-	Tc-99 m labelled modified recombinant tissue plasminogen activator uptake in acute deep venous thrombosis
Bril W. S.	-	A mouse model for inhibitor development in mild hemophilia A
Brill-Edwards P.	-	Ability of d-dimer to reduce the need for diagnostic imaging in patients with suspected pulmonary embolism: A randomized trial
Brink Van Den R. B. A.	-	Optimal intensity of oral anti-coagulant therapy in patients with mechanical heart valves
Brinkmann T.	-	Quantification of tissue factor pathway inhibitor (TFPI) in human seminal plasma and in human ovarian follicular fluid
	-	Expression of wild type tissue factor pathway inhibitor (TFPI) and the first natural TFPI mutant ([P151L]) in insect and mammalian cells
Briquel M. E.	-	Thrombinography can differentiate bleeding from nonbleeding patients with prolonged APTT
Brisset A. C.	-	Shedding of active tissue factor (TF) by rat aortic smooth muscle cells (SMCs) undergoing apoptosis
Brister S. J.	-	Plasma 13-HODE: A novel and powerful predictor of cardiovascular disease (CVD) risk and severity
Brittain J. E.	-	CD47 stimulated sickle erythrocytes adhere to activated monocytes via a novel contribution of the a 4b 1 integrin from each cell type
Brittan H.	-	Characterization of novel platelet and procoagulant activities from Bothrops cotiara snake venom
Brittenden J.	-	Enhanced in vivo platelet activation in patients with peripheral arterial disease, and differences between intermittent claudication and critical limb ischemia
	-	The CAVA study: a double-blind randomized controlled trial of clopidogrel and aspirin vs. aspirin alone in patients with intermittent claudication undergoing peripheral percutaneous transluminal angioplasty
Brizard A.	-	Recurrent thrombosis in a young patient with a left-sided inferior vena cava and factor V Leiden and prothrombin 20210A
Brochon J. C.	-	The active conformations of Factor VIIa and Factor IXa: biochemical, biophysical, chemical and crystallographic studies
Brockmann M. A.	-	Monitoring platelet concentrates (PCs) during storage by functional and immunological tests
	-	Transfusion of activated platelets: increase of platelet-leukocyte binding in vivo
Brodin E.	-	Inflammation and endothelial dysfunction in patients with carotid stenosis
Brodin E.	-	Interactions between tissue factor pathway inhibitor (TFPI) and lipoprotein lipase (LPL) in metabolism of very low density lipoproteins (VLDL)
Broekman M. J.	-	CD39 ecto-nucleotidase activity (metabolizing ATP to ADP to AMP) constitutes a homeostatic mechanism for control of platelet reactivity, depending on the ratio of ADPase to ATPase activity. Results from patients with coronary artery disease
Brogen H.	-	Platelets synthesize large amounts of PAI-1
Brogi D.	-	Emerging prognostic factors in ischemic heart disease
Brogi D.	-	High plasma homocysteine concentrations in cerebrovascular patients with Fabry disease
	-	Protein Z levels in acute coronary syndromes
Brogren H.	-	Quantification of ADP and ATP receptor expression in human platelets
Brohée D.	-	The biphasic waveform of APTT optical clot formation profile is related with the activation of FVII but not with ISTH DIC score or classical coagulation activation parameters
Brohult J.	-	A comparison of spiral computed tomography and latex agglutination D-dimer assay in acute pulmonary embolism using pulmonary arteriography as Gold Standard
	-	Spiral computed tomography has a higher sensitivity and specificity than d-dimer in the diagnosis of acute pulmonary embolism
Brom J.	-	Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery
	-	Prevention of venous thromboembolism in orthopedic trauma patients receiving heparin thromboprophylaxis – a substudy analysis of autopsy-confirmed fatal pulmonary embolism
	-	Combined analysis of 2 studies on the clinical outcome over 6 months in patients with symptomatic acute deep vein thrombosis initially treated with one low-molecular-weight heparin
Brooker L. A.	-	Venous thrombosis in children
Brookfield C.	-	The measurement and prevalence of antibodies to prothrombin in patients screened for anti-phospholipid syndrome
Brookfield C.	-	Isolated sustained elevated antib2 Glycoprotein 1 antibodies: association with primary anti-phospholipid syndrome and thrombotic events
	-	Risk factors for carotid artery plaque formation in premenopausal women with systemic lupus erythematosus
	-	The relationship between risk factors for premature vascular disease in systemic lupus erythematosis (SLE) with secondary anti-phospholipid syndrome (APS)
Brooks S.	-	DRVVT testing for lupus identification: a comparison of two methods
Brooks S. V.	-	Combined modality inhibitor eradication in a patient with mild hemophilia A and comparison of methods of inhibitor monitoring
Brophy M.T.	-	The Veterans Affairs Cooperative Studies Program's ‘80+ Hemorrhagic Cohort Study
Bros A.	-	A new co-operative effect of low molecular weight polysaccharides and cell surface heparin sulfate in enhancing bFGF-induced endothelial cell differentiation
Brosstad F.	-	Family history of thromboembolism does not identify children with thrombophilia – A cross-sectional study
Brouwer J. L. P.	-	Arterial thromboembolism (ATE) in patients with systemic lupus erythematosus (SLE): the contribution of inherited thrombophilic risk factors
	-	The contribution of inherited thrombophilic risk factors to venous thromboembolism (VTE) in patients with systemic lupus erythematosus (SLE)
Brouwers G. J.	-	Association between genetic variability of von Willebrand factor and peripheral atherosclerosis: the Rotterdam Study
	-	Genetic variability of von Willebrand factor and coronary heart disease: the Rotterdam Study
Brouwers E.	-	Characterization of monoclonal antibodies that inhibit either the activation of proCPU (TAFI) or the activity of CPU (TAFIa)
Browett P.	-	Protein Z-dependent protease inhibitor (ZPI) deficiency: a new thrombotic risk factor?
Brown K.	-	Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors
Brown B.	-	Gene therapy for hemophilia A with high-capacity adenoviral vectors: preclinical evaluation in hemophilic mice and dogs
Brown S.A.	-	Identification of a family with discrepant von Willebrand factor collagen binding assays (VWF:CB)
Brown P. R.	-	Transport of blood samples through a pneumatic tube system causes loss of platelet function
Brown B.	-	Treatment of severe canine hemophilia A by helper-dependent adenoviral-mediated gene therapy
Brown P. R.	-	Marked variation in d-Dimer concentration as determined by four different assays
Brown J. M.	-	Complement C3 and its relationship to features of the insulin resistance syndrome and cardiovascular disease
Brown S. A.	-	Increased VWF antigen clearance in partial quantitative von Willebrand factor deficiency and reporting of a familial tendency
Brown B.	-	The use of three hemophilia A mouse models to illustrate strain-specific differences in immune responses to FVIII protein replacement via protein infusion or adenoviral gene therapy
Brown S. A.	-	Combined modality inhibitor eradication in a patient with mild hemophilia A and comparison of methods of inhibitor monitoring
Brown D.	-	Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis – a meta-analysis
Browne M.	-	Thrombolytic therapy with tissue plasminogen activator (tPA), analysis of safety and outcome in children
Browne M.	-	Anti-coagulation clinics for children achieve improved warfarin management
Brox J.	-	Association of the -159 C-to-T polymorphism in the CD14 promoter with variations in serum lipoproteins in healthy subjects
	-	The relationship between sh-CRP and reactivity of monocytes and various blood parameters known to play an important role in atherogenesis
Broze G. J.	-	Competitive activation of IX and X by the extrinsic pathway. Studies of the differential regulation of enzyme and products by antithrombin III and tissue factor pathway inhibitor reveal that active IXa is a major reaction product of this pathway
	-	Heritability of clotting factors and the prothrombotic state: results from a large thrombophilic pedigree of French Canadian descent with Type I protein C deficiency
Broze G.	-	Protein Z
Broze Jr G. J.	-	Evaluation of protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) plasma levels and the in vitro inhibition of activated factor X by PZ/ZPI in patients with autoimmune aPL
	-	Autoantibodies to TFPI are associated with definite APS but not with infection-related aPL
Bru S.	-	Age influence on D-Dimer in a large normal French population: the FITENAT study
Bruckdorfer K. R.	-	The influence of tissue factor (CD142) on endothelial cell apoptosis and proliferation
Brückmann M.	-	The impact of factor V Leiden on the endothelial cytokine response to coagulation activation modulated by drotrecogin alfa (activated)
	-	MCP-1 as early marker for cell activation in septic patients
	-	TIMP-1, TIMP-2 and MMP-9 as prognostic markers for clinical outcome in sepsis
Brueckmann M.	-	Drotrecogin alfa (activated) inhibits degradation of cytokine-mRNA in an endothelial model of inflammation
	-	Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotregocin alfa (activated)
Brufatto N.	-	Factor Xa is profoundly protected from Antithrombin–arixtra and antithrombin-Lovenox when incorporated into the prothrombinase complex
Brugge J. M.	-	Theoretical and experimental investigation of the D2194G subsitution in the C2 domain of coagulation factor V
Brugge J.	-	Functional characterization of recombinant factor V molecules mimicking the R2-haplotype
Brugge J. M.	-	Impaired anticoagulant activity of factor V accounts for a large fraction of the APC resistance associated with the FV Leiden (R506Q) and R2 (H1299R) mutations
Brüggemann L. W.	-	Tissue factor itself is vital for the development of cell types with constitutive tissue factor expression but not for cell types without such expression
Brüggemann L. W.	-	Coagulant phenotype determines the outcome of septic peritonitis
Brugnini A.	-	Association between recurrent pregnancy loss and prothrombotic gene polymorphisms
Brummel K. E.	-	How factor VIIa works in hemophilia
Brummel K.	-	What is all that thrombin for?
Brummel K. E.	-	Systemic enzymatic activity in blood?
Brummel K. E.	-	Phenotypic thrombin generation: a composite view
Brummitt D.	-	An unusual case of acquired giant platelet syndrome with May Hegglin features and Hermansky-Pudlak-like platelets
Brunelli C.	-	Blood glutathione detects pro-oxidant patterns in mild hyperhomocysteinemia associated with atherothrombotic vascular events
Brunet P.	-	Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration
	-	The uremic retention solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair in vitro
Brunet A.	-	Intravenous immunoglobulins G modulate calcium signals, von Willebrand factor secretion and nitric oxide metabolism in human endothelial cells
	-	Thrombomodulin regulates activity, localization and expression of nitric oxide synthase inhuman umbilical vein endothelial cells (HUVECs)
Bruni V.	-	Effects of HRT with estradiolvalerate 2-mg + levonorgestrel 75 µg (NUVELLE®) on clotting and lipid profile
Bruty S. J.	-	Does thromboelastography demonstrate hypercoagulability in patients with both a clinical history of thrombosis and the lupus anti-coagulant antibody?
Bruty S.	-	Factor VII Padua: diagnosis based on differential laboratory tests
Bryan S.	-	European action on anti-coagulation – cost effectiveness of computer assisted anti-coagulant dosage
Bryant J. W.	-	Inhibition of human prothrombinase by PD0313052 reveals advantages of active site-directed factor Xa inhibition
Brzewski M.	-	Hemorrhage into the right cerebella hemisphere in hemophiliac boy with factor VIII inhibitor
Brzezinska-Kolarz B.	-	Factor V Leiden and blood coagulation at the site of microvascular injury in coumadin treated patients and healthy control
	-	Factor VIII activity and blood coagulation in patients on long-term oral anticoagulation
Brzosko S.	-	Effect of extra virgin olive oil on experimental thrombosis and primary haemostasis in rats
Bucciantini M. S.	-	Effects of HRT with estradiolvalerate 2-mg + levonorgestrel 75 µg (NUVELLE®) on clotting and lipid profile
Bucciarelli P.	-	Genetically defined protein S (PS) deficiency is associated with venous thrombosis
	-	Intruterine Growth Restriction (IUGR) and thrombophilic polymorphisms
Bucha E.	-	Determination of direct thrombin inhibitors like hirudin in plasma – Comparison of the Ecarin Chromogenic Assay (ECA) with the Ecarin Clotting Time (ECT) and the Activated Partial Thromboplastin Time (APTT)
	-	PADA-HIT: A new POCT method for ultra-fast detection of HIT II antibodies
Bucha E.	-	PADA – fast and quantitative monitoring of blood platelet adhesiveness
Buchanan M. R.	-	Plasma 13-HODE: A novel and powerful predictor of cardiovascular disease (CVD) risk and severity
Buchmuller-Cordier A.	-	Predictive factors of cancer discovery after deep-vein thrombosis: a 8-years follow-up study
Buczko W.	-	Antithrombotic action of perindopril in experimental venous thrombosis in young rats
Buczko P.	-	Antithrombotic action of perindopril in experimental venous thrombosis in young rats
Buczko W.	-	Biological and pharmacokinetic activity of the new recombinant thrombolytic and anthithrombotic agent RGD SAK-K2-HIR
	-	Thrombolytic effect of AT1 receptor antagonists – losartan and its metabolite EXP 3174 in rat
	-	Effect of angiotensin II and their metabolites on hemostasis in rats
Budde U.	-	Cone and plate(let) analyzer as a diagnostic tool in various types of thrombotic thrombocytopenic purpura and haemolytic uremic syndrome
	-	Comparative expression of recombinant wildtype and mutant von Willebrand factor cleaving protease ADAMTS13
	-	Comparison of von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF-collagen-binding-assays in VWF/FVIII-concentrates
	-	Determination of High-Molecular-Weight von Willebrand factor multimers and their impact on specific VWF-activities in VWF/FVIII-concentrates
	-	Co-segregation of Von Willebrands disease type 1 phenotype and Von Willebrand factor gene haplotypes: first results from the multicenter study molecular and clinical markers for the diagnosis and management of type 1 Von Willebrands disease
Budde U.	-	An improved multimeric analysis identifies a subgroup of patients with Type 1 von Willebrand disease characterized by reduced VWF:RCo/Ag ratio
Budde U.	-	Multicenter comparison of assays for von Willebrand factor-cleaving protease (ADAMTS13) activity
	-	Splice site mutations of the von Willebrand factor gene in patients previously diagnosed with von Willebrand disease type 1
	-	Molecular and clinical markers for the diagnosis and management of type 1 von Willebrand's disease (VWD): The progress of a European collaboration
Buechner S.	-	High plasma homocysteine concentrations in cerebrovascular patients with Fabry disease
Bueller H.	-	Combined analysis of 2 studies on the clinical outcome over 6 months in patients with symptomatic acute deep vein thrombosis initially treated with one low-molecular-weight heparin
Buendía P.	-	A promising therapeutic strategy in acute promyelocytic leukemia (APL): disruption of MEK/ERK, arsenic and retinoids
Buendía P.	-	Increased tissue factor expression in monocytes from patients with anti-phospholipid syndrome depends on NFkB activation
Buenjemia J.	-	Reliability of patient self-testing and point-of-care testing with the Harmony (TM) INR monitoring system: a 3-year study
Buensuceso C.	-	The scaffold function of b3 integrins regulates integrin signaling
Buggle CH.	-	Platelet function under aspirin, clopidogrel and both after ischemic stroke. A case-crossover study
Buil A.	-	Heritability of plasma antiphospholipid antibodies
	-	A quantitative trait locus on chromosome 11 is the major genetic determinant of homocysteine plasma levels. Results from the GAIT Project
Buil A.	-	Genetic dissection of thrombin-activatable fibrinolysis inhibitor (TAFI)
Buiting M. T.	-	Potential reversal agents for the long-acting pentasaccharide idraparinux
Bukharov I. B.	-	Optimization model for type IV collagen degradation: determination of kinetic constants
Bulargina T.	-	False-positive reaction upon determination of d-dimer by ELISA
Bulikova A.	-	Risk of venous thromboembolism during pregnancy and puerperium in women with homozygous form of F V Leiden
	-	rFVIIa NovoSeven®– Hemostatic agent not only for hemophiliacs
Bullens S.	-	Differential use of variable domains of D3H44 antibody in binding to tissue factor or to an anti-idiotypic antibody
Buller H. R.	-	The risk of pregnancy complications in women from families with thrombophilic defects
Büller H. R.	-	Brain natriuretic peptide (BNP) as a predictor of adverse outcome in patients with pulmonary embolism
	-	Thrombophilia strikes at all ages
Buller H.R.	-	Comparison of 2 d-dimer assays (MDA®d-dimer and Tina-quant®d-dimer) in patients with suspected recurrent deep venous thrombosis – an interim analysis
Büller H. R.	-	Effectiveness of excluding pulmonary embolism in the elderly by using a clinical decision rule and d-dimer
Buller H. R.	-	Clopidogrel suppresses rebound coagulation after discontinuation of enoxaparin treatment in patients with acute coronary syndromes
Büller H. R.	-	The balance between the benefits and risks of treatment with vitamin K antagonists as perceived by patients
Buller H. R.	-	Venous and arterial thromboembolic risk in first degree family members of patients with elevated plasma levels of clotting factor VIII:c
	-	Screening of high factor VIII levels is not recommended in patients with recently diagnosed pulmonary embolism
Büller H. R.	-	Malignancy and low-molecular weight-heparin therapy: the MALT trial
Buller H. R.	-	Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Preliminary results of a family cohort study
Büller H. R.	-	The optimal duration of treatment with vitamin K antagonists in patients with a first episode of venous thromboembolism: a decision analytic approach
	-	Patients' valuation of outcomes after venous thromboembolism
	-	Physicians' interpretation of ventilation-perfusion lung scans
Buller H. R.	-	Increased risk for venous thromboembolism and myocardial infarction in family members of patients with prothrombin 20210 A mutation
	-	Risk assessment of venous thromboembolism in pregnant women with factor V Leiden, prothrombin 20210 A mutation, elevated factor VIII levels or mild hyperhomocystinaemia
	-	Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremities: survival, risk factors and post–thrombotis syndrome
Büller H. R.	-	Effect of hyperhomocysteinemia on coagulation activation and endothelial cell activation
	-	High levels of coagulation factors IX or XI: risk factors for pulmonary embolism?
Buller H. R.	-	Diagnostic performances of two new d-dimer assays in the diagnostic work-up of patients with suspected pulmonary emboli
Buller H.	-	The prevalence and prognostic importance of elevated cardiac troponins in patients with acute submassive pulmonary embolism
Buller H. R.	-	Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
Büller H. R.	-	Subsequent diagnosis of malignancy in patients presenting with an idiopathic venous thromboembolism – a number needed to screen and decision analysis based on the results of a prospective study
Buller H.	-	Drugs sources and clinical benefits: Arixtra a new model
Büller H. R.	-	d-dimer as a prognostic marker in patients with pulmonary embolism
Buller H.	-	New parenteral anticoagulants
Buller H.	-	Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review
Buller H. R.	-	Absolute risk of venous thromboembolism (VTE) associated with a single or combined thrombophilic disorder. Preliminary results of a family cohort study
	-	Observer variability in the assessment of clinical probability in patients with suspected pulmonary embolism
Büller H. R.	-	Day-care or short-stay surgery and venous thromboemolism: an overview
Bullinger M.	-	Health-related quality-of-life assessment in the hemophilia population
	-	Validation of the first hemophilia-specific quality of life questionnaire for children and adolescents (Hemo-QoL)
	-	Health-related quality of life in adults with hemophilia: the patient perspective
Bullorsky E.	-	High levels of factors VIII, IX and XI in patients with a thromboembolic event
	-	Safety considerations of Enoxaparin as an alternative to oral anti-coagulants in high risk cardioembolic patients with a programed surgical procedure. SWITCH trial
Bulut M.	-	Effects of 6,7-dihydroxy-3-phenylcoumarin and warfarin on thromboplastin induced experimental disseminated intravascular coagulation
Bundred N. J.	-	Increase in platelet VEGF release in early breast cancer
Buntinx F.	-	The quality of care in the management of oral anti-coagulation therapy by the Belgian general practitioner
Bura A.	-	Bilateral deep-vein thrombosis and cancer: prospective study of 103 patients
Burakowska B.	-	Compression ultrasound in diagnosis of asymptomatic deep venous thrombosis
Burger P.	-	Inhibition of metalloproteases during platelet storage leads to better platelet recovery and improved platelet function upon transfusion
Burgess C.	-	Subcutaneous administration of protein C
	-	Transient lupus anti-coagulant directed against factor II
Burggraaf J.	-	A novel method to accurately measure collagen/serotonin-induced platelet aggregation by whole blood impedance aggregometry in humans
	-	Evaluation of a bed-side device to assess the APTT for heparin monitoring in infants
Burke N.	-	Timing of initial administration of prophylaxis against deep vein thrombosis in patients following hip or knee surgery
Burke J. P.	-	Genetic susceptibility of venous thromboembolism: role of the procoagulant, anticoagulant, fibrinolytic, and acute inflammation pathways
Burke G. L.	-	C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study (CHS)
Bürkle M. A.	-	Magnetofection – a highly efficient tool for endothelial gene transfer and antisense oligonucleotide delivery in vitro and in vivo
	-	A cytochrome P450 2C8/9-derived EDHF inhibits platelet adhesion to endothelial cells in vitro
Burman J. F.	-	A patient with factor V Leiden who rapidly developed fatal heparin induced thrombocytopenia
	-	Endothelial cell damage as shown by raised soluble-thrombomodulin and total von Willebrand factor antigen levels during heparin induced thrombocytopenia
Burman J.	-	Teicoplanin-dependent platelet antibodies as a cause of severe thrombocytopenia
Burman J. F.	-	Thrombin potential in heparin induced thrombocytopenia
Burmeister Getz E.	-	Evaluation of IgG formation to trace mammalian proteins in hemophilia patients treated with a recombinant therapeutic protein preparation
	-	Pharmacokinetics of functional von Willebrand Factor (VWF) with infusion of Koate-DVI® in patients with von Willebrand's Disease (VWD)
Burnand K.	-	Enhanced thrombus recanalization and resolution after vascular endothelial growth factor (VEGF) naked DNA gene transfer
Burnell M.	-	A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer
Burnouf T.	-	Coagulation and endothelium activation in patients with scrub typhus
Burrus L. T.	-	Plasminogen activator inhibitor reversibly inhibits cell-surface single-chain but not two-chain urokinase associated plasminogen activation
Burstein C.	-	Discrepancies in potency assessment of B-domain deleted recombinant factor VIII among different one-stage factor VIII clotting assays
Burton J. H.	-	APTT transmittance waveform analysis in a cohort of septic patients
Burton I. E.	-	Increase in platelet VEGF release in early breast cancer
Burton E.C.	-	Rates of recurrent thromboembolism and bleeding in venous thromboembolism patients treated with long-term LMWH
Burton E.	-	A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer
Busabaratana M.	-	The factor V R2 allele (A4070G), factor V gene G1628A mutation, factor V Hong Kong (A1090G), factor V Cambridge (G1091C), the tissue factor pathway inhibitor gene C536T mutation and the risk of venous thrombosis in Thai patients
Busetto R.	-	Anti-thrombin III levels in cynomolgus monkey recipients of a life-supporting porcine renal xenograft
Busqué A.	-	Transmission electron microscopy of granulocyte inclusions in genetically confirmed MYH9-related disorders
Busque L.	-	Haematologic factors potentially implicated in the pathophysiology of avascular necrosis of the femoral head (AVN): hypercoagulability as a cause of AVN
Bussel J. B.	-	Thrombosis in patients with immune thrombocytopenic purpura (ITP): a case series
Butchart E. G.	-	Warfarin-resistant factor VII is a potential risk factor for thromboembolism (TE) after prosthetic heart valve replacement
Butenas S.	-	Systemic enzymatic activity in blood?
	-	How factor VIIa works in hemophilia
Butenas S.	-	What is all that thrombin for?
Butine M.D.	-	A randomized, double-blind, placebo-controlled study of the safety and pharmacokinetics of a single dose of recombinant Factor XIII in healthy volunteers
Butler R.	-	Eleven novel mutations in non-Jewish factor XI deficient kindreds detected by SSCP with heteroduplex analysis followed by sequencing
Butler L. M.	-	Sequential adhesion of platelets and then leukocytes from blood flowing over collagen in simple laminar and disturbed flow
Butler P.	-	Tc-99 m labelled modified recombinant tissue plasminogen activator uptake in acute deep venous thrombosis
Butt C.	-	Combined carrier status of prothrombin 20210 A and factor XIII-A L34 alleles as a strong risk factor for myocardial infarction: evidence of a gene–gene interaction
Buturovic-Ponikvar J.	-	Utility of in vitro closure time (PFA-100TM) for evaluating platelet related primary hemostasis in dialysis patients
Bux J.	-	Human antibody against CD11b inhibits platelet–leukocyte interaction under high shear
Bychkovskaya I. B.	-	Unusual persistent cell damages in irradiated rat endothelium as a model in study pathophysiology of atherosclerosis and thrombosis
Bykowska K.	-	Polymorphisms of the factor VII gene and ischemic stroke in young adults
	-	Lupus anticoagulant and elevated anticardiolipin antibodies as risk factors for venous thromboembolism
Byrne G. J.	-	Increase in platelet VEGF release in early breast cancer
Byrne C. D.	-	Reduced sensitivity to aPC after fish oil supplementation via increased LDL and platelet microparticle formation
Byrne G. J.	-	Anticoagulant prophylaxis usage in cancer patients undergoing treatment
Bzowska M.	-	Sialic acid and lipid contents of low density lipoprotein in relation to platelet receptor activity